[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 202
1. Yanik B, Tur BS, Kutlay S: Metastatic vertebral tumor misdiagnosed in magnetic resonance imaging as benign degenerative bone marrow changes: a case report. Rheumatol Int; 2005 Jun;25(5):384-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic vertebral tumor misdiagnosed in magnetic resonance imaging as benign degenerative bone marrow changes: a case report.
  • We report a man with low back and right groin pain as a result of metastatic breast carcinoma which was misdiagnosed in magnetic resonance imaging as benign degenerative changes.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Marrow / pathology. Bone Neoplasms / secondary. Breast Neoplasms, Male / pathology. Diagnostic Errors. Lumbar Vertebrae / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Humans. Low Back Pain / etiology. Male. Middle Aged. Radiography. Radionuclide Imaging

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1985 Oct;157(1):157-66 [3875878.001]
  • [Cites] Clin Nucl Med. 2000 Aug;25(8):647-9 [10944033.001]
  • [Cites] Radiology. 1988 Jan;166(1 Pt 1):193-9 [3336678.001]
  • [Cites] Ann Intern Med. 2002 Oct 15;137(8):678-87 [12379069.001]
  • [Cites] Cancer. 1987 Mar 15;59(6):1112-6 [3815285.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Dec 25;52(12):1611-9 [1488288.001]
  • [Cites] AJR Am J Roentgenol. 1990 Jul;155(1):85-8 [2112871.001]
  • (PMID = 15449024.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


2. Chung EM, Cube R, Hall GJ, González C, Stocker JT, Glassman LM: From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation. Radiographics; 2009 May-Jun;29(3):907-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation.
  • The spectrum of breast lesions in children and adolescents varies markedly from that for adults, with the former lesions being overwhelmingly benign.
  • A breast mass in a young boy or girl may arise from normal and abnormal breast development.
  • After onset of puberty, most cases of breast enlargement arise from benign fibroadenoma in girls and gynecomastia in boys.
  • These conditions have specific imaging appearances, although juvenile (often giant) fibroadenoma cannot be distinguished from phyllodes tumor, which can be benign or malignant.
  • A diagnosis of juvenile papillomatosis (a benign lesion) portends later development of breast cancer, and patients with this condition should be closely monitored.
  • Malignant lesions of the breast in children are rare.
  • The most common primary breast malignancy is malignant phyllodes tumor.
  • Primary breast carcinoma is exceedingly rare in the pediatric age group, but its imaging appearance in children is the same as seen in adults and is different from that of almost all benign lesions.
  • In girls, diagnostic interventions may injure the developing breast and cause subsequent disfigurement.
  • Given this risk and the low prevalence of malignant disease in this population, a prudent course should be followed in the diagnosis of breast lesions.
  • [MeSH-major] Breast Diseases / radiography
  • [MeSH-minor] Adolescent. Breast / abnormalities. Breast / anatomy & histology. Breast / growth & development. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / secondary. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / ultrasonography. Child. Child, Preschool. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Fibroadenoma / radiography. Granular Cell Tumor / diagnosis. Granular Cell Tumor / pathology. Granular Cell Tumor / radiography. Gynecomastia / pathology. Gynecomastia / radiography. Humans. Infant. Infant, Newborn. Male. Nipples / abnormalities. Papilloma / diagnosis. Papilloma / pathology. Papilloma / radiography. Phyllodes Tumor / diagnosis. Phyllodes Tumor / pathology. Phyllodes Tumor / radiography. Puberty. Puberty, Precocious / diagnosis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448124.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


3. Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D'Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N: Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res; 2006 Sep 1;12(17):5158-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cripto-1 as a novel serologic marker for breast and colon cancer.
  • We evaluated whether CR-1 is present in the plasma of patients with breast and colon cancer, and if it can represent a new biomarker for these malignancies.
  • EXPERIMENTAL DESIGN: We determined CR-1 plasma levels using a sandwich-type ELISA in 21 healthy volunteers, 54 patients with breast cancer, 33 patients with colon carcinoma, and 21 patients with benign breast lesions.
  • A statistically significant increase in the levels of plasma CR-1 was found in patients with colon carcinoma (4.68+/-3.5 ng/mL) and in patients with breast carcinoma (2.97+/-1.48 ng/mL; P<0.001).
  • Although moderate levels of plasma CR-1 were found in women with benign lesions of the breast (1.7+/-0.99 ng/mL), these levels were significantly lower than in patients with breast cancer (P<0.001).
  • Finally, immunohistochemical analysis and real-time reverse transcription-PCR confirmed strong positivity for CR-1 in colon and/or breast tumor tissues.
  • CONCLUSION: This study suggests that plasma CR-1 might represent a novel biomarker for the detection of breast and colon carcinomas.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Colonic Neoplasms / blood. Colonic Neoplasms / diagnosis. Epidermal Growth Factor / blood. Membrane Glycoproteins / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Animals. Enzyme-Linked Immunosorbent Assay / methods. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Intercellular Signaling Peptides and Proteins. Male. Mice. Mice, Transgenic. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951234.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


Advertisement
4. Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM, Wang F: Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer; 2008 Aug 1;123(3):543-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forced expression of Cks1 and Cks2 in benign prostate tumor epithelial cells promoted cell population growth.
  • Knockdown of Cks1 expression in malignant prostate tumor cells inhibited proliferation, anchorage-independent growth, and migration activities, whereas knockdown of Cks2 expression induced programmed cell death and inhibited the tumorigenicity.
  • Collectively, the data suggest that elevated expression of Cks1 contributes to the tumorigenicity of prostate tumor cells by promoting cell growth and elevated expression of Cks2 protects the cells from apoptosis.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2005 Feb;41(2):105-16 [15695111.001]
  • [Cites] Mol Gen Genet. 1986 Feb;202(2):291-3 [3010051.001]
  • [Cites] Mol Cell Biol. 1989 May;9(5):2034-41 [2664468.001]
  • [Cites] Genes Dev. 1990 Aug;4(8):1332-44 [2227411.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5369-78 [9393762.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;59:135-76 [9427842.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):98-104 [10360827.001]
  • [Cites] Am J Pathol. 2004 Dec;165(6):2147-55 [15579456.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55348-54 [15513912.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):51-63 [15652749.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):310-6 [16116475.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2461-9 [16353136.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):599-607 [16572426.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1511-24 [16705040.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):521-31 [16865252.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):668-75 [16826582.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9986-94 [17047061.001]
  • [Cites] J Urol. 2006 Nov;176(5):2285-9 [17070313.001]
  • [Cites] Int J Oncol. 2006 Dec;29(6):1337-47 [17088971.001]
  • [Cites] J Biol Chem. 2007 Jan 5;282(1):390-6 [17092932.001]
  • [Cites] Development. 2007 Feb;134(4):723-34 [17215304.001]
  • [Cites] FEBS Lett. 2007 Mar 20;581(6):1166-72 [17336302.001]
  • [Cites] Mod Pathol. 2007 Apr;20(4):497-507 [17384652.001]
  • [Cites] Breast Cancer Res. 2007;9(2):R25 [17428314.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1336-46 [15717322.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2249-61 [15900300.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5246-51 [15897880.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R737-44 [16168119.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):17-26 [16341208.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):148-68 [11237531.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):321-4 [11231585.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):639-50 [11463388.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):41-7 [12507555.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cell Cycle. 2003 Jan-Feb;2(1):59-63 [12695690.001]
  • [Cites] Science. 2003 Apr 25;300(5619):647-50 [12714746.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4936-44 [12941818.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8784-90 [14695195.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] Lab Invest. 2004 May;84(5):588-96 [15064772.001]
  • [Cites] Genes Dev. 2004 Apr 15;18(8):862-76 [15078817.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3507-14 [3322810.001]
  • (PMID = 18498131.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096824-01A1; United States / NCI NIH HHS / CA / R01 CA096824-01A1; United States / NCI NIH HHS / CA / CA096824-05; United States / NCI NIH HHS / CA / R01 CA096824-05; United States / NCI NIH HHS / CA / R56 CA096824; United States / NCI NIH HHS / CA / CA096824; United States / NCI NIH HHS / CA / R01 CA096824
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKS1B protein, human; 0 / CKS2 protein, human; 0 / Carrier Proteins; 0 / Cell Cycle Proteins; 0 / DNA, Complementary; 0 / RNA, Messenger; EC 2.7.- / Protein Kinases; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / CDC28 Protein Kinase, S cerevisiae; EC 2.7.11.22 / Cks1 protein, mouse; EC 2.7.11.22 / Cks2 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinases
  • [Other-IDs] NLM/ NIHMS93124; NLM/ PMC3262990
  •  go-up   go-down


5. Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F: Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. World J Gastroenterol; 2007 Dec 21;13(47):6356-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred patients with histologically confirmed malignant or benign hepatic tumor (maximum size 5 cm) were analyzed.
  • The cut-off of the gray value differences between tumor and normal liver tissue was established using Receiver Operating Characteristic (ROC) analysis 64-line multi-slice computed tomography served as reference method in all cases.
  • RESULTS: One hundred patients with 59 malignant (43 colon, 5 breast, 2 endocrine metastases, 7 hepatocellular carcinomas and 2 kidney cancers) and 41 benign (15 hemangiomas, 7 focal nodular hyperplasias, 5 complicated cysts, 2 abscesses and 12 circumscribed fatty changes) tumors were included.
  • The late venous phase proved to be the most sensitive for classification of the tumor type.
  • Of the 41 benign tumors, 37 were classified as true negative and 4 as false negative, which corresponds to a specificity of 90.2%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Germany. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Angiography. Male. Middle Aged. Observer Variation. Predictive Value of Tests. Prospective Studies. ROC Curve. Reproducibility of Results. Sensitivity and Specificity. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081224.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  • [Other-IDs] NLM/ PMC4205454
  •  go-up   go-down


6. Pruthi RS, Lentz AC, Sand M, Kouba E, Wallen EM: Impact of marital status in patients undergoing radical cystectomy for bladder cancer. World J Urol; 2009 Aug;27(4):573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Married (vs. unmarried) individuals have improved health status and longer life expectancies in a variety of benign and malignant disease states, including prostate, breast, head/neck, and lung cancers.
  • Married individuals (vs. unmarried) were more often male (84 vs. 62%) and had a higher BMI (28.1 vs. 25.9).
  • These findings may support the evidence (observed in other tumor types and other disease states) that married persons present earlier than unmarried individuals, and this may help explain the improved survival outcomes that have been observed in married patients with bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Marital Status. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Cohort Studies. Creatinine / blood. Female. Follow-Up Studies. Hematocrit. Humans. Length of Stay. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Sep 15;104(6):1188-94 [16078264.001]
  • [Cites] Soc Sci Med. 2003 Dec;57(11):2137-47 [14512244.001]
  • [Cites] Psychooncology. 2008 Sep;17(9):869-76 [18033697.001]
  • [Cites] J Urol. 1996 Nov;156(5):1696-70 [8863573.001]
  • [Cites] Ann Epidemiol. 2000 May;10(4):224-38 [10854957.001]
  • [Cites] Health Psychol. 1988;7(3):269-97 [3289916.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]
  • [Cites] JAMA. 1987 Dec 4;258(21):3125-30 [3669259.001]
  • [Cites] World J Surg. 2003 Mar;27(3):304-8 [12607056.001]
  • [Cites] Am J Epidemiol. 1982 Jul;116(1):123-40 [7102648.001]
  • (PMID = 19219612.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


7. Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF: Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. Med Clin (Barc); 2009 Oct 3;133(12):449-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
  • BACKGROUND: Malignant mesothelioma (MM) is a highly aggressive tumor that can be difficult to diagnose, resulting in a delayed diagnosis in some cases.
  • Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in the diagnosis of MM.
  • PATIENTS AND METHODS: Pleural fluid SMRP concentration was measured in 68 patients: 47 had malignant pleural effusions (18 MM and 29 metastatic effusion) and 21 had benign pleural effusion (8 infectious disease and 13 idiopathic effusion).
  • Mann-Whitney analysis was used to compare SMRP values according to the etiology of the effusion.
  • RESULTS: Pleural fluid SMRP concentration was significantly higher in patients with malignant pleural effusion than in those with benign effusion (P=0.02).
  • CONCLUSIONS: Soluble mesothelin-related peptide measurement in pleural fluid may aid in the diagnosis of patients presenting with pleural effusion.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Hematologic Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Membrane Glycoproteins / analysis. Mesothelioma / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Female. GPI-Linked Proteins. Humans. Male. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric


8. Dupuis C, Coard KC: A review of granular cell tumours at the University Hospital of the West Indies: 1965-2006. West Indian Med J; 2009 Mar;58(2):138-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are usually benign, but as they are infrequently diagnosed preoperatively, they may be confused clinically with malignant lesions.
  • Of these, 99patients were female and 23 male, providing a male:female ratio of l to 4.3.
  • Lesions ranged in size from 0.2 cm to 10 cm in greatest dimension, the average size being 1.85 cm and were found in a diverse array of anatomic locations, the most common being the vulva, breast and tongue.
  • The correct clinical diagnosis was proffered preoperatively in only one case.
  • In contrast, a malignant diagnosis was suggested in 19 cases.
  • In particular lesions of the tongue accounted for fewer than expected, while lesions of the breast and vulva were considerably increased.
  • [MeSH-major] Granular Cell Tumor / epidemiology. Granular Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Child. Child, Preschool. Female. Hospitals, University. Humans. Infant. Infant, Newborn. Male. Middle Aged. Tongue Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology. West Indies / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21866599.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


9. Behera MA, Dai Q, Garde R, Saner C, Jungheim E, Price TM: Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells. Am J Physiol Endocrinol Metab; 2009 Nov;297(5):E1089-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.
  • The effects of progesterone on breast epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects.
  • The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in breast epithelial cells lacking nuclear receptors.
  • This study examined possible nongenomic effects of progesterone in breast epithelia by using MCF-10A cells known to lack nuclear progesterone receptor expression.
  • Our study demonstrates a nongenomic action of progesterone on benign breast epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Cell Cardiol. 1995 Oct;27(10):2167-76 [8576933.001]
  • [Cites] Genes Dev. 1995 Sep 15;9(18):2266-78 [7557380.001]
  • [Cites] Breast Cancer Res Treat. 1997 Sep;45(2):121-33 [9342437.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):223-30 [9344602.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12567-75 [10212235.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Nov;97(3):278-88 [16154741.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):843-54 [16326395.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):174-8 [16413775.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):5837-44 [16407197.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27 [16466914.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):925-35 [16361271.001]
  • [Cites] Apoptosis. 2006 Apr;11(4):473-85 [16532373.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17 [16829228.001]
  • [Cites] Maturitas. 2006 Jul 20;54(4):327-34 [16806749.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83 [16460873.001]
  • [Cites] Mol Endocrinol. 2006 Dec;20(12):3146-64 [16959873.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):2723-36 [17332059.001]
  • [Cites] Cell Prolif. 2007 Oct;40(5):721-40 [17877612.001]
  • [Cites] Biol Chem. 2007 Oct;388(10):1113-9 [17937626.001]
  • [Cites] Mitochondrion. 2007 Dec;7(6):399-401 [17881297.001]
  • [Cites] Methods. 2008 Mar;44(3):222-8 [18314052.001]
  • [Cites] Breast. 2008 Apr;17(2):172-9 [17928227.001]
  • [Cites] Cell Res. 2009 Jan;19(1):140-8 [19079362.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 [10599719.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):867-72 [10706096.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):936-43 [10706108.001]
  • [Cites] Oncology. 2000;59 Suppl 1:39-44 [11096355.001]
  • [Cites] Mol Endocrinol. 2001 Feb;15(2):255-70 [11158332.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103 [11420134.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3071-82 [12130573.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105 [12160089.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]
  • [Cites] Mol Endocrinol. 2003 Jan;17(1):117-27 [12511611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6 [12574519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42 [12601167.001]
  • [Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):155-63 [12644308.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):25-30 [12650698.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 23;1658(1-2):141-7 [15282185.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Aug;71(8):2942-5 [4528490.001]
  • [Cites] Nature. 1975 Feb 27;253(5494):746-7 [1113869.001]
  • [Cites] Cancer Res. 1978 Aug;38(8):2434-7 [667841.001]
  • [Cites] Exp Cell Res. 1988 Sep;178(1):143-53 [3409975.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Endocrinol. 1990 Dec;4(12):1833-40 [2082185.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):340-3 [8275464.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3868-77 [8033109.001]
  • [Cites] J Exp Med. 1994 Sep 1;180(3):917-23 [8064240.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8 [9024102.001]
  • (PMID = 19690070.001).
  • [ISSN] 1522-1555
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / 1R03HD-052770-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Inhibitor of Differentiation Protein 1; 0 / Protein Synthesis Inhibitors; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 4G7DS2Q64Y / Progesterone; 8L70Q75FXE / Adenosine Triphosphate; 98600C0908 / Cycloheximide; EC 3.4.21.- / Kallikreins; EC 3.4.22.- / Caspases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


10. Hossain D, Meiers I, Qian J, MacLennan GT, Bostwick DG: Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases. Arch Pathol Lab Med; 2008 Nov;132(11):1729-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Prostatic stromal hyperplasia with atypia consists of 1 or more ill-defined, uncircumscribed, hyperplastic stromal nodules, with variable numbers of atypical, bizarre giant cells, with vacuolated nuclei, smudged chromatin, and frequent multinucleation infiltrating around benign acini.
  • CONCLUSIONS: Prostatic stromal hyperplasia with atypia is a rare, benign lesion, composed of degenerative myocytes with atypia that is histologically and clinically reminiscent of benign counterparts in the myometrium, breast, vulva, vagina, and elsewhere.
  • Recognition of this distinctive entity should allow separation from phyllodes tumor and sarcoma of the prostate.
  • The phrase stromal tumor of uncertain malignant potential is inappropriate for this benign tumor, and its use is discouraged.
  • [MeSH-major] Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Stromal Cells / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Nucleus / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Muscle Cells / metabolism. Muscle Cells / pathology. Receptors, Androgen / metabolism. Retrospective Studies. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976007.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Vimentin
  •  go-up   go-down


11. Lauwers K, Bestman TJ, Bergmans G, Molderez C: Granular cell tumour of the male breast. Acta Chir Belg; 2008 Jan-Feb;108(1):112-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumour of the male breast.
  • Granular cell tumour (GCT) is a rare neoplasm that can be found in multiple sites throughout the body.
  • Occasionally GCT is located in the breast.
  • In general, it appears as a singular benign lesion, although it can be multi-focal and rare cases with malignant behaviour have been reported.
  • We report a rare case of granular cell tumour of the nipple in the male breast, treated by wide local excision.
  • [MeSH-major] Breast Neoplasms, Male / surgery. Granular Cell Tumor / surgery
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Male. Nipples

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18411585.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


12. Abaffy T, Duncan R, Riemer DD, Tietje O, Elgart G, Milikowski C, DeFazio RA: Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process. PLoS One; 2010 Nov 04;5(11):e13813
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Discovering new melanoma biomarkers would improve early detection and diagnosis.
  • Volatiles released from fresh biopsy tissue of melanoma and benign naevus were compared based on their difference in frequency distribution and their expression level.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2000 Feb 15;72(4):747-56 [10701259.001]
  • [Cites] J Am Chem Soc. 2010 Mar 24;132(11):3642-3 [20196537.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2002 Jan 29;357(1417):17-23 [11839178.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):184-91 [12752626.001]
  • [Cites] Trends Biochem Sci. 2003 Jun;28(6):329-35 [12826405.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):489-99 [14585259.001]
  • [Cites] Lancet. 2004 Feb 28;363(9410):728-30 [15005091.001]
  • [Cites] Prev Med. 2004 Apr;38(4):382-7 [15020171.001]
  • [Cites] Environ Health Perspect. 2004 May;112(7):A396-7 [15159211.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):551-61 [15229480.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):269-77 [15261821.001]
  • [Cites] Nature. 1966 Nov 26;212(5065):933-5 [4306794.001]
  • [Cites] J Biol Chem. 1980 Nov 10;255(21):10493-501 [7430132.001]
  • [Cites] Anticancer Res. 1985 Jan-Feb;5(1):1-30 [3888043.001]
  • [Cites] Mutat Res. 1989 Jan;219(1):71-9 [2911273.001]
  • [Cites] Biochem Pharmacol. 1995 Dec 22;50(12):1955-62 [8849320.001]
  • [Cites] Science. 1996 Jul 5;273(5271):59-63 [8658196.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11895-901 [9115250.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2291-8 [10325416.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3855-60 [10463569.001]
  • [Cites] J Invest Dermatol. 1964 Aug;43:111-3 [14196302.001]
  • [Cites] Biochemistry. 2004 Nov 16;43(45):14332-9 [15533037.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] J Invest Dermatol. 2006 Dec;126(12):2565-75 [17108903.001]
  • [Cites] Mass Spectrom Rev. 2007 Jan-Feb;26(1):51-78 [16921475.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]
  • [Cites] Am J Clin Nutr. 2007 Apr;85(4):946-9 [17413090.001]
  • [Cites] Cancer Biomark. 2007;3(2):95-109 [17522431.001]
  • [Cites] Int J Epidemiol. 2008 Apr;37 Suppl 1:i23-30 [18381390.001]
  • [Cites] Skin Res Technol. 2008 May;14(2):226-36 [18412567.001]
  • [Cites] PLoS Med. 2008 Jun 3;5(6):e120 [18532874.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):774-80 [18594325.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2446-55 [18729182.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(4):780-91 [18637798.001]
  • [Cites] J Am Chem Soc. 2008 Oct 29;130(43):14111-3 [18831549.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1054-6 [18948945.001]
  • [Cites] Lung Cancer. 2009 Feb;63(2):164-8 [18599152.001]
  • [Cites] Can Fam Physician. 2009 Jan;55(1):24; autor reply 24 [19155361.001]
  • [Cites] Anal Bioanal Chem. 2009 Feb;393(3):781-95 [18836706.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]
  • [Cites] J Am Soc Mass Spectrom. 2009 Mar;20(3):464-8 [19070510.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1524-33 [19342374.001]
  • [Cites] Nat Rev Genet. 2009 May;10(5):295-304 [19308066.001]
  • [Cites] Cancer Control. 2009 Jul;16(3):200-18 [19556960.001]
  • [Cites] Eur Respir J. 2009 Jul;34(1):261-75 [19567608.001]
  • [Cites] BMC Cancer. 2009;9:348 [19788722.001]
  • [Cites] Pigment Cell Melanoma Res. 2009 Dec;22(6):750-60 [19735457.001]
  • [Cites] Pigment Cell Melanoma Res. 2010 Feb;23(1):64-71 [19788535.001]
  • [Cites] Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):613-20 [20143319.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):520-4 [11286617.001]
  • (PMID = 21079799.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA132046-02; United States / NCI NIH HHS / CA / R21 CA132046; United States / NCI NIH HHS / CA / R21CA 132046; United States / NCI NIH HHS / CA / R21 CA132046-01A1; United States / NCI NIH HHS / CA / R21 CA132046-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Volatile Organic Compounds
  • [Other-IDs] NLM/ PMC2973952
  •  go-up   go-down


13. Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P: Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology. J Nucl Med; 2008 Sep;49(9):1429-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
  • Our objective was to evaluate features of these foci associated with benign or malignant etiology.
  • Variables evaluated were maximum standard uptake values (SUV max), purity (absence of (18)F-FDG-avid foci in nonhilar mediastinal nodes), symmetry (difference between left and right side SUV max), the primary tumor, node size determined by CT, and, in those who participated in 2 studies, stability of uptake over time.
  • The gold standard was histologic diagnosis or long-term clinical follow-up (range, 19-41 mo; mean, 25 mo).
  • On univariate analysis, variables associated with malignancy were SUV max (6.6+/-4.1 vs. 3.5+/-1.0 for benign, P<0.001; t test); impurity (P<0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P=0.027); and change in uptake between scans 1 and 2 (change in SUV=2.7+/-2.1 vs. 0.73+/-1.1 for benign, P < 0.01; t test).
  • Variables associated with benign etiology were: symmetry (difference between left and right sides=0.57+/-0.54 for benign vs. 1.8+/-1.7 for malignant, P<0.01), purity, and colorectal primary (75% of colorectal were benign vs. 34% of breast, 49% of lymphoma, and 37% of other, P=0.030; chi(2) test).
  • CONCLUSION: In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a benign etiology.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2009 Mar;50(3):489-90 [19223415.001]
  • (PMID = 18765585.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Jeryong K, Jinsun L, Hyegyong K, Eilsung C, Jiyoung S, Insang S, Moonsang A, Jiyeon K, Jaeeun H: Total endoscopic thyroidectomy with bilateral breast areola and ipsilateral axillary (BBIA) approach. World J Surg; 2008 Nov;32(11):2488-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total endoscopic thyroidectomy with bilateral breast areola and ipsilateral axillary (BBIA) approach.
  • The present study reviews our experiences with endoscopic thyroidectomy using bilateral breast areola and ipsilateral axillary (BBIA) approach to evaluate its safety and feasibility.
  • METHODS: From June 2003 through November 2007, the study group was comprised of 68 consecutive patients with benign thyroid nodules (66 women; mean age, 33.28 +/- 10.3 (range, 15-72) years).
  • RESULTS: The mean maximum diameter of the tumor was 3.14 +/- 1.61 (range, 1-10.7) cm.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Feasibility Studies. Female. Humans. Length of Stay. Male. Middle Aged. Nipples. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2006 Oct;116(10):1745-8 [17003721.001]
  • [Cites] Thyroid. 2002 Aug;12(8):703-6 [12225638.001]
  • [Cites] Am J Surg. 2001 Jun;181(6):567-70 [11513788.001]
  • [Cites] J Surg Oncol. 1998 Nov;69(3):178-80 [9846506.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12 ):1741-5 [12140635.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):82-5 [11044518.001]
  • [Cites] Anesth Analg. 1997 May;84(5):1154-6 [9141952.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:68s-71s [12487256.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1075-8 [15490052.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):189-95 [12595044.001]
  • [Cites] Anesth Analg. 2000 Mar;90(3):760-2 [10702471.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):875 [8696772.001]
  • [Cites] Surg Laparosc Endosc. 1994 Apr;4(2):92-9 [8180774.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:64s-67s [12487255.001]
  • [Cites] Surgery. 2000 Dec;128(6):1035-42 [11114640.001]
  • [Cites] J Am Coll Surg. 2000 Sep;191(3):336-40 [10989910.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]
  • (PMID = 18668282.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G: Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol; 2009;26(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical significance of serum interleukin-6 (IL-6) and its correlation with cystatin C (Cyst C), an endogenous inhibitor of cysteine proteinase cathepsin K, was investigated by immunoassays in patients with bone metastasis from breast cancer (BCa) or prostate cancer (PCa).
  • Mean IL-6 levels were also higher in PCa patients and in patients with benign prostatic hyperplasia (BPH) than in HS while Cyst C resulted significantly higher in PCa but not in BPH patients as compared to HS.
  • [MeSH-major] Bone Neoplasms / blood. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Cystatin C / blood. Interleukin-6 / blood. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use. Female. Humans. Imidazoles / therapeutic use. Male. Middle Aged. Osteoporosis / blood. Osteoporosis / complications. Prostate-Specific Antigen / blood. ROC Curve

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone. 2005 Nov;37(5):601-6 [16112634.001]
  • [Cites] Breast Cancer Res Treat. 2007 Apr;102(2):129-35 [16927176.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 1:S5 [17634144.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1A):23-6 [16475674.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):753-62 [15792117.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] Urology. 2001 Dec;58(6):1008-15 [11744478.001]
  • [Cites] Bone. 2004 Sep;35(3):689-96 [15336605.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2032-42 [11344203.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):84-9 [10763147.001]
  • [Cites] Cancer Lett. 2006 Apr 28;235(2):159-76 [15893421.001]
  • [Cites] Biochimie. 2008 Feb;90(2):208-26 [17935853.001]
  • [Cites] Oncology. 2005;69(1):35-43 [16088233.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2312-6 [15150588.001]
  • [Cites] Palliat Med. 2003 Sep;17(6):539-53 [14526888.001]
  • [Cites] Acta Physiol Scand. 1997 Sep;161(1):81-92 [9381954.001]
  • [Cites] Oncologist. 2004;9(6):687-95 [15561812.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1911-28 [17849470.001]
  • [Cites] Eur Urol. 2007 May;51(5):1202-16 [17182170.001]
  • [Cites] Clin Biochem. 2007 Mar;40(5-6):383-91 [17316593.001]
  • [Cites] Bull World Health Organ. 2001;79(4):373-4 [11357217.001]
  • [Cites] J Clin Pharmacol. 2002 Nov;42(11):1228-36 [12412821.001]
  • [Cites] J Chemother. 2005 Oct;17(5):555-9 [16323446.001]
  • [Cites] BJU Int. 2006 Jul;98(1):189-96 [16831167.001]
  • [Cites] Bone. 2004 Mar;34(3):412-24 [15003789.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):718-29 [14991763.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):986-9 [16533874.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 17;360(1):199-204 [17592728.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):642-6 [12494472.001]
  • [Cites] J Cell Biochem. 2005 Jun 1;95(3):497-505 [15838876.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):246-61 [10344214.001]
  • [Cites] J Pathol. 2004 Jan;202(1):41-9 [14694520.001]
  • [Cites] J Endocrinol Invest. 2002 Jun;25(6):539-46 [12109626.001]
  • [Cites] Cancer Treat Rev. 2008 Apr;34(2):183-92 [18061356.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60 [14746813.001]
  • (PMID = 18461289.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Cystatin C; 0 / Diphosphonates; 0 / Imidazoles; 0 / Interleukin-6; 6XC1PAD3KF / zoledronic acid; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


16. Ismail MF, Aly MS, Khaled HM, Mohamed HM: Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer. Ger Med Sci; 2009;7:Doc03
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
  • Breast cancer is a leading cause of cancer-related deaths in women worldwide.
  • Amplification of the two oncogenes HER-2/neu and c-myc and inactivation of the tumor suppressor gene p53 are frequently encountered in breast carcinomas.
  • The study was conducted on 34 tissue samples obtained from 33 females and 1 male with breast carcinomas and 17 samples obtained from 16 females and 1 male with benign breast lesions.
  • Results revealed that the level of HER-2/neu, c-myc and p53 in the malignant group was significantly increased as compared to the benign group.
  • The sensitivity of the investigated markers significantly increased with larger tumor size.
  • Concerning tumor grade, HER-2/neu and p53 showed a significant increase in low-grade tumors whereas c-myc showed a highly significant increase in high-grade tumors.
  • [MeSH-major] Breast Neoplasms / genetics. In Situ Hybridization, Fluorescence / methods. Proto-Oncogene Proteins c-myc / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biopsy. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / genetics. Egypt / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Nucleic Acid Amplification Techniques / methods. Prevalence. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Jan;156(1):183-91 [10623666.001]
  • [Cites] Diagn Mol Pathol. 2007 Dec;16(4):207-10 [18043283.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):211-21 [10832591.001]
  • [Cites] Indian J Exp Biol. 2000 Mar;38(3):225-30 [10927863.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] Acta Oncol. 2000;39(3):327-33 [10987229.001]
  • [Cites] Endocr Relat Cancer. 2000 Sep;7(3):143-64 [11021963.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6093-101 [11156522.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6102-14 [11156523.001]
  • [Cites] Int J Cancer. 2001 Jul 20;95(4):266-70 [11400121.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):337-44 [11553865.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1481-8 [11888924.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):690-4 [12548612.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1612-9 [15083194.001]
  • [Cites] J Pathol. 2004 Aug;203(4):918-26 [15258994.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):246-55 [15323142.001]
  • [Cites] Nature. 1986 Feb 27-Mar 5;319(6056):783-4 [3005871.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 [1351679.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Cell Growth Differ. 1993 Jan;4(1):41-7 [8424905.001]
  • [Cites] Curr Opin Genet Dev. 1995 Feb;5(1):97-104 [7749333.001]
  • [Cites] J Pathol. 1995 Nov;177(3):225-32 [8551383.001]
  • [Cites] Oncogene. 1996 Jul 4;13(1):63-72 [8700555.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):323-9 [9563780.001]
  • [Cites] Breast Cancer Res Treat. 1998 May;49(1):35-9 [9694609.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):100-8 [9739012.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Am J Clin Pathol. 1999 Oct;112(4):459-69 [10510669.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):900-5 [15643600.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1909-17 [15753390.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):633-41 [15756435.001]
  • [Cites] Histopathology. 2005 Apr;46(4):431-41 [15810955.001]
  • [Cites] Rev Med Chir Soc Med Nat Iasi. 2004 Jul-Sep;108(3):657-61 [15832994.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):634-9 [16021569.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jul;47(3):340-2 [16295419.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):433-9 [16297088.001]
  • [Cites] Clin Exp Metastasis. 2005;22(6):495-502 [16320112.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1058-79 [16457687.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):424-8 [16497871.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]
  • [Cites] Oncologist. 2006 Sep;11(8):857-67 [16951389.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):973-80 [16964393.001]
  • [Cites] Int J Biol Markers. 2006 Jul-Sep;21(3):131-40 [17013794.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 1998 Dec;29(4):399-401 [10743237.001]
  • (PMID = 19675743.001).
  • [ISSN] 1612-3174
  • [Journal-full-title] German medical science : GMS e-journal
  • [ISO-abbreviation] Ger Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2716551
  • [Keywords] NOTNLM ; HER-2/neu / breast cancer / c-myc / fluorescent in situ hybridization (FISH) / genetic alterations / p53
  •  go-up   go-down


17. Drees R, Hünigen H, Wagner S, Schnorr J, Plendl J, Taupitz M: Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology. Vet Comp Oncol; 2008 Sep;6(3):151-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The peripheral washout sign was first described in delayed dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using a small molecular contrast medium in solid lesions of the human breast and liver.
  • It was found to be 100% specific for malignant lesions and could therefore potentially be used as an additional noninvasive diagnostic tool differentiating malignant from benign lesions.
  • [MeSH-minor] Animals. Cell Line, Tumor. Male. Rats. Rats, Inbred Strains. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178675.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


18. Mouton WG, Kienle Y, Muggli B, Naef M, Wagner HE: Tumors associated with superficial thrombophlebitis. Vasa; 2009 May;38(2):167-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To assess the incidence of malignant tumors in patients with thrombophlebitis of the leg with regard to potential early tumor detection.
  • RESULTS: There were 18 patients (12.9%) suffering from thrombophlebitis in association with a malignant tumor: breast cancer in seven patients, colon carcinoma and haematologic cancer in four, skin cancer in three patients and one case each of oesophageal, prostatic, kidney and neck cancer .
  • In two patients thrombophlebitis preceded the diagnosis of the malignancy.
  • Superficial thrombophlebitis may have been associated in four cases (2.9%) with a benign tumor.
  • CONCLUSIONS: Breast, colonic, haematological and skin cancer were mainly associated with superficial thrombophlebitis in our patients.
  • In case of a thrombophlebitis without a known malignancy a thorough clinical examination with special regard to skin, breast and abdomen is mandatory.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Cross-Sectional Studies. Early Diagnosis. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Ultrasonography, Doppler, Duplex. Venous Insufficiency / complications. Venous Insufficiency / epidemiology. Venous Insufficiency / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588305.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK: 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope; 2005 Jun;115(6):1074-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the prevalence of incidental thyroid F-fluorodeoxyglucose (FDG) uptake in positron emission tomogram (PET) scan for evaluation in cancer patients and the role of standard uptake value (SUV) measurement in differentiation of thyroid malignancy from benign disease.
  • Cytologic diagnosis was available in 32 of 45 focal thyroid FDG uptakes.
  • In 16 (50%) patients, the tumor was found to be malignant; 14 were papillary thyroid carcinoma (surgically confirmed in 7 cases), 2 were metastatic tumor from breast and esophagus.
  • Sixteen were cytologically diagnosed as follicular cell lesions: follicular neoplasm (n = 2), nodular hyperplasia (n = 7), indeterminate follicular lesion (n = 7).
  • There was no significant difference in maximum SUV between benign and malignant nodules.
  • From 45 patients with diffuse thyroid FDG uptake, presumptive diagnosis of chronic thyroiditis was possible in 34 patients by clinical and laboratory findings.
  • CONCLUSION: Our data suggest that a cytologic diagnosis of focal thyroid FDG-PET incidentaloma regardless of SUV is mandatory considering the very high prevalence of thyroid malignancy.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radionuclide imaging. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Thyroid Nodule / radionuclide imaging. Thyroiditis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933524.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Moon HJ, Kim MJ, Kwak JY, Yoon JH, Kim SJ, Sohn YM, Kim EK: Malignant lesions initially categorized as probably benign breast lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics. Ultrasound Med Biol; 2010 Apr;36(4):551-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lesions initially categorized as probably benign breast lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics.
  • The primary objective of this study was to review the ultrasonographic features of BI-RADS category 3 ("probably benign") lesions that eventually proved to be malignant.
  • Thirty-two (0.8%) of 4000 women with lesions that were initially classified as "probably benign" proved to be malignant and formed the study group.
  • There was no statistical difference in the mean age, mean size of lesions, or tumor stage between patients who underwent early biopsy (n = 19) or biopsy after 6 months (n = 13).
  • [MeSH-major] Biopsy / statistics & numerical data. Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Ultrasonography, Mammary / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Female. Humans. Korea / epidemiology. Male. Middle Aged. Prevalence. Reproducibility of Results. Retrospective Studies. Risk Assessment. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20350681.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Hafner C, Schmiemann V, Ruetten A, Coras B, Landthaler M, Reifenberger J, Vogt T: PTCH mutations are not mainly involved in the pathogenesis of sporadic trichoblastomas. Hum Pathol; 2007 Oct;38(10):1496-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trichoblastomas are rare, benign tumors of the appendix in human skin.
  • This mutation at codon 1,315 represents an already described PTCH germline polymorphism and results in a heterozygous Pro to Leu substitution in the tumor.
  • The Pro/Leu polymorphism in germline is associated with a higher risk for breast cancer, but a potential contribution to the tumorigenesis of trichoblastoma is unknown.
  • The genetic basis of this rare appendageal tumor remains elusive.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597182.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


22. Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovich C, Jankowiak R: Potential biomarker for early risk assessment of prostate cancer. Prostate; 2006 Oct 1;66(14):1565-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This damage leads to mutations that can initiate breast and prostate cancer.
  • To determine whether this damage occurs in humans, urine samples from men with prostate cancer and benign urological conditions, and healthy controls were analyzed.
  • RESULTS: 4-OHE1-1-N3Ade was detected at higher levels in samples from subjects with prostate cancer (n = 7) and benign urological conditions (n = 4) compared to healthy males (n = 5).
  • [MeSH-major] Biomarkers, Tumor / urine. DNA Adducts / urine. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / urine
  • [MeSH-minor] Antibodies, Monoclonal. Early Diagnosis. Electrophoresis, Capillary. Estradiol / analogs & derivatives. Estradiol / chemistry. Estradiol / immunology. Estradiol / urine. Estrogens, Catechol. Humans. Hydroxyestrones / chemistry. Hydroxyestrones / immunology. Hydroxyestrones / urine. Male. Risk Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16894534.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / PHS HHS / / 1 P20 RP15563; United States / NCI NIH HHS / CA / 2P01 CA49210-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / DNA Adducts; 0 / Estrogens, Catechol; 0 / Hydroxyestrones; 3131-23-5 / 4-hydroxyestrone; 4TI98Z838E / Estradiol; C3ZO03450E / 4-hydroxyestradiol
  •  go-up   go-down


23. Tumminello FM, Flandina C, Crescimanno M, Leto G: Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Biomed Pharmacother; 2008 Feb;62(2):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical significance of serum cathepsin K and cystatin C was assessed in patients with breast cancer (BCa) or prostate cancer (PCa) with confined disease (M0) or bone metastasis (BM).
  • In PCa patients, cathepsin K concentrations did not significantly differ from those measured in sex matched HS or in patients with benign prostatic hyperplasia (BPH).
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / secondary. Cathepsins / blood. Cystatins / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Bone Density Conservation Agents / pharmacology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Case-Control Studies. Cathepsin K. Cystatin C. Diphosphonates / pharmacology. Disease Progression. Drug Monitoring / methods. Enzyme-Linked Immunosorbent Assay. Female. Humans. Imidazoles / pharmacology. Male. Middle Aged. Osteoporosis / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. ROC Curve

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728092.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / CST3 protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K
  •  go-up   go-down


24. Gunasekera RS, Sewgobind K, Desai S, Dunn L, Black HS, McKeehan WL, Patil B: Lycopene and lutein inhibit proliferation in rat prostate carcinoma cells. Nutr Cancer; 2007;58(2):171-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consumption of lycopene, a carotenoid without provitamin A activity, has been associated with a lower risk of prostate and breast cancer.
  • The effects of grapefruit-derived and commercial lycopene and lutein preparations on androgen independent cultured malignant type II tumor cells [Dunning R3327AT3 or AT3 cells (androgen-responsive, slow-growing tumor cells with well developed epithelium and stroma)] were compared to their benign parent type I tumor epithelial cells (DTE).
  • No such effect was observed when benign DTE cells were examined, demonstrating selective inhibition of extremely malignant AT3 prostate cancer cells relative to their benign parent.
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Citrus paradisi. Dose-Response Relationship, Drug. Humans. Male. Rats. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640163.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene; X72A60C9MT / Lutein
  •  go-up   go-down


25. Neves Cde O, Soares AB, Costa AF, de Araujo VC, Furuse C, Juliano PB, Altemani A: CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):172-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD10 is a cell surface peptidase expressed in a wide variety of normal and neoplastic tissues, including breast myoepithelial cells.
  • In neoplastic myoepithelial cells, CD10 expression was found in 25.71% of benign and 32.43% of malignant neoplasms.
  • The high expression of CD10 by this carcinoma can be a valuable tool to separate EMEC from the tubular variant of adenoid cystic carcinomas in small incisional biopsies, where the precise diagnosis may be impossible.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752720.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


26. Kondi-Pafitis A, Kairi-Vassilatou E, Grapsa D, Kalkounou I, Vassilikostas G, Psichogios I: A large benign vascular neoplasm of the male breast. A case report and review of the literature. Eur J Gynaecol Oncol; 2005;26(4):454-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large benign vascular neoplasm of the male breast. A case report and review of the literature.
  • Breast hemangiomas are extremely rare neoplasms in the male population.
  • We report a case of a 77-year old man with a breast hemangioma which was detected in physical examination as a small nodule ten years after a chest injury.
  • The final histological diagnosis was hemangioma of the breast, 6 cm in the largest diameter.
  • To our knowledge, this is the largest benign vascular breast neoplasm in a male patient reported up to date.
  • The rarity of the lesion and its differential diagnosis from angiosarcoma are discussed while the problems encountered in the correct diagnosis and classification of this tumor are also presented.
  • The need for extreme caution in the interpretation of the histological characteristics of all palpable vascular tumors of the breast is emphasized.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Hemangioma / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Mastectomy, Segmental

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gynaecol Oncol. 2005;26(6):667; author reply 667-8 [16398236.001]
  • (PMID = 16122203.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 10
  •  go-up   go-down


27. Porcel JM, Salud A, Vives M, Esquerda A, Rodríguez-Panadero F: Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions. Clin Biochem; 2005 Nov;38(11):1031-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate whether pleural levels of the soluble oncoprotein 185 HER-2 (sp185(HER-2)), individually or in combination with CEA and CA 15-3, were useful for the diagnosis of malignant effusions.
  • DESIGN AND METHODS: Levels of CEA, CA 15-3, and sp185(HER-2) were measured in the pleural fluid from 135 malignant and 103 benign effusions.
  • Thresholds of these tumor markers were chosen for a diagnostic specificity of >or=99%.
  • RESULTS: Pleural sp185(HER-2) levels greater than 25 ng/mL were observed in 20% of breast and 10% of lung adenocarcinomas, and predicted a malignant effusion with a sensitivity of 7% and a likelihood ratio of 7.6.
  • Only 1 patient with breast adenocarcinoma among 45 cytology-negative malignant effusions had sp185(HER-2) above the diagnostic cutoff point.
  • [MeSH-major] Biomarkers, Tumor / analysis. Pleural Effusion, Malignant / diagnosis. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Breast Neoplasms / diagnosis. Carcinoembryonic Antigen / analysis. False Negative Reactions. Humans. Likelihood Functions. Lung Neoplasms / diagnosis. Male. Middle Aged. Mucin-1 / analysis. Pleural Effusion / chemistry. Pleural Effusion / diagnosis. Sensitivity and Specificity

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925354.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


28. Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M: Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience. Urology; 2007 Apr;69(4):637-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 34 adrenalectomies were performed in 32 patients for incidental adrenal masses discovered at primary tumor diagnosis or during follow-up.
  • The primary tumors diagnosed were 13 cases of lung carcinoma, 9 of renal cell carcinoma, 2 of colorectal carcinoma, 2 of bladder carcinoma, and 1 each of ovarian carcinoma, breast cancer, gastric cancer, and melanoma.
  • Two patients had no history of a primary tumor.
  • The male/female ratio was 1.9:1.
  • The mean tumor size was 4.3 cm (range 1.5 to 9).
  • The microscopic analysis revealed 22 malign lesions (64.7%) and 12 cases of benign pathologic features (35.3%).
  • [MeSH-minor] Adult. Female. Humans. Incidental Findings. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445640.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ: Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem; 2008 Jan;54(1):44-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
  • METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):203-9 [14499014.001]
  • [Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Dis Markers. 2003-2004;19(4-5):185-95 [15258333.001]
  • [Cites] Clin Chem. 2004 Dec;50(12):2398-401 [15563493.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):142-9 [15685197.001]
  • [Cites] Clin Chem. 2005 Aug;51(8):1525-8 [15951319.001]
  • [Cites] Clin Chem. 2005 Sep;51(9):1637-49 [16002455.001]
  • [Cites] Proteomics. 2006 Mar;6(5):1676-80 [16447157.001]
  • [Cites] Clin Chem. 2006 Apr;52(4):771-2; author reply 772 [16595832.001]
  • [Cites] Proteomics. 2006 May;6(10):3189-98 [16586434.001]
  • [Cites] Clin Chem. 2006 Jul;52(7):1218-22 [16675505.001]
  • [Cites] Biometrics. 2006 Jun;62(2):589-97 [16918924.001]
  • [Cites] J Proteome Res. 2006 Sep;5(9):2079-82 [16944917.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Feb;3(2):96-103 [17299447.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):645-56 [17303688.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3262-77 [16052621.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1835-43 [12324514.001]
  • [CommentIn] Clin Chem. 2008 Jan;54(1):3-5 [18160722.001]
  • [CommentIn] Clin Chem. 2008 Jan;54(1):6-7 [18160723.001]
  • (PMID = 17981926.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 084986; United States / NCI NIH HHS / CA / CA 84968; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / CA 86368; United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA086323; United States / NCI NIH HHS / CA / U24 CA086368; United States / NCI NIH HHS / CA / U01 CA086368; United States / NCI NIH HHS / CA / CA 86359; United States / NCI NIH HHS / CA / CA 86402; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / CA 86323; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / CA 85067; United States / NCI NIH HHS / CA / U01 CA084986
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS371877; NLM/ PMC3354530
  •  go-up   go-down


30. Blumenthal GM, Dennis PA: PTEN hamartoma tumor syndromes. Eur J Hum Genet; 2008 Nov;16(11):1289-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN hamartoma tumor syndromes.
  • The PTEN hamartoma tumor syndromes (PHTS) are a collection of rare clinical syndromes characterized by germline mutations of the tumor suppressor PTEN.
  • These syndromes are driven by cellular overgrowth, leading to benign hamartomas in virtually any organ.
  • Cowden syndrome (CS), the prototypic PHTS syndrome, is associated with increased susceptibility to breast, thyroid, and endometrial cancer.
  • [MeSH-minor] Cell Movement. Cell Proliferation. Cell Survival. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 10 / metabolism. Female. Humans. Male. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Protein Kinases / genetics. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. TOR Serine-Threonine Kinases


31. Suzuki H, Graziano DF, McKolanis J, Finn OJ: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res; 2005 Feb 15;11(4):1521-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cyclin B1-derived peptides were shown by us to be targets of tumor-specific CD8(+) T cells in patients with breast and head and neck cancer.
  • We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a tumor-specific antigen by analyzing its ability to elicit T cell-dependent humoral immune responses in vivo in patients with different types of tumors.
  • EXPERIMENTAL DESIGN: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with breast, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody.
  • We also analyzed patients with benign lung disease, premalignant disease, and a known history of heavy smoking.
  • Antibodies in patients with breast and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA.
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Colonic Neoplasms / blood. Colonic Neoplasms / immunology. Colonic Neoplasms / metabolism. Cyclin B1. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunohistochemistry. Lung Neoplasms / blood. Lung Neoplasms / immunology. Lung Neoplasms / metabolism. Male. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / metabolism. Smoking / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746055.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 090440
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / Immunoglobulin A; 0 / Immunoglobulin G
  •  go-up   go-down


32. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep; 2005 Oct;14(4):1013-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential tumor marker.
  • S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (breast, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in benign and non-cancerous diseases, representing 850 preoperative cases.
  • S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with benign tumors and in those with non-cancerous diseases.
  • Significant correlations between concentration and activity level were only found in healthy individuals, in patients with benign tumors, and in some patients with malignancies, i.e. leukaemia, and breast and gastric cancers.
  • We conclude that S-TK1 concentration is a more sensitive tumor marker in solid malignancies than is STK activity.
  • [MeSH-major] Biomarkers, Tumor. Neoplasms / blood. Neoplasms / diagnosis. Thymidine Kinase / blood
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142366.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
  •  go-up   go-down


33. Li BJ, Huang XP, Wei WD, Wang JY, Su XD, Zhang X, Hong WS, Tang J, Zhang LJ, Long H, Yang MT, Rong TH: [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. Ai Zheng; 2005 Jun;24(6):735-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].
  • BACKGROUND & OBJECTIVE: Breast cancer may undergo metastasis in early phase.
  • Distant metastasis, especially bone metastasis, may influence prognosis of breast cancer patients.
  • This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with breast cancer.
  • METHODS: Expression of CK19 mRNA in bone marrows of 65 breast cancer patients, 15 benign breast disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  • Correlation of CK19 mRNA expression to clinicopathologic features of the 65 breast cancer patients was analyzed.
  • RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65 breast cancer patients, and 0 in both benign breast disease patients and healthy volunteers.
  • Expression of CK19 mRNA was positively correlated with tumor size and clinical stage (P < 0.05), but was not related to age and lymph node status (P > 0.05).
  • CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with breast cancer.
  • The detection may help to select proper therapy and predict prognosis of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Keratin-19 / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946491.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


34. Di Carlo A, Terracciano D, Mariano A, Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol; 2005 May;26(5):1363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, several MMPs were implicated in creating an environment that supports the initiation and maintenance of tumor growth.
  • Of these patients, 22 had malignant pleural effusion, consisting of 11 breast carcinomas and 11 lung carcinomas (7 squamous cell carcinomas and 4 adenocarcinomas), and 8 patients had benign effusions.
  • The MMP-9/MMP-2 ratio was enhanced in cancer patients compared with benign diseases and healthy individuals.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Pleural Effusion / enzymology. Pleural Effusion / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809729.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


35. Nassar A, Amin MB, Sexton DG, Cohen C: Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, AMACR has been demonstrated to be overexpressed in localized and metastatic prostate cancer and in high-grade prostatic intraepithelial neoplasia but not in normal prostatic glands, suggesting that it may be an important tumor marker.
  • This study examines AMACR expression in a variety of human cancers to assess its viability as a tumor marker in the clinical setting.
  • Cancers studied included breast (94 cases), prostate (38), lung (28), endometrium (27), colon (29), ovary (26), and melanoma (21).
  • A section of prostate cancer and prostatic intraepithelial neoplasia was used as positive control.
  • AMACR protein overexpression was found in several cancers, including prostate (34/38 [89.5%]), colon (13/29 [44.8%]), lung (4/28 [14.3%]), melanoma (2/21 [9.5%]), endometrium (2/27 [7.4%]), and breast (3/94 [3.2%]).
  • AMACR expression was not present in any of the normal tissues nor in benign prostatic tissue associated with prostate carcinomas.
  • This study suggests that AMACR is potentially an important tumor marker, particularly for prostate and colon cancer.
  • It may be a useful adjunct to an immunohistochemical panel employed in the differential diagnosis of colon versus ovarian and breast carcinoma; the latter two infrequently express AMACR.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082251.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


36. Shah SN: Giant myofibroblastoma of breast: a case report. Indian J Pathol Microbiol; 2007 Jul;50(3):583-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant myofibroblastoma of breast: a case report.
  • Myofibroblastoma of the breast is a very rare benign neoplasm usually seen in elderly male and is of very small size.
  • A 40 year old nulliparous woman was admitted with chief complain of massive enlargement of left breast.
  • The case was clinically diagnosed as Phyllodes tumor Left mastectomy was done.
  • The tumor was histopathologically and immunohistochemically diagnosed as Myofibroblastoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Neoplasms, Muscle Tissue / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883145.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


37. Shams TM, Samaka RM, Shams ME: Maspin protein expression: a special feature of papillary thyroid carcinoma. J Egypt Natl Canc Inst; 2006 Sep;18(3):274-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Mammary serine protease inhibitor (Maspin) is down regulated in breast and prostate cancers and is considered as a tumor suppressor gene.
  • On the contrary, it is over expressed in pancreatic and ovarian carcinomas and is reported to be an oncogene rather than a tumor suppressor gene.
  • The studies of maspin expression in thyroid neoplasia, the focus of this study, are limited.
  • We, therefore, carried out this work in order to detect the frequency and pattern of maspin expression in thyroid neoplasia.
  • MATERIAL & METHODS: An immunohistochemical approach was performed on 63 thyroid specimens showing different benign and malignant thyroid lesions.
  • There was no statistically significant relation between maspin positive cases and the studied clinicopathological parameters including patient's age, sex and tumor stage.
  • On the other hand, it was statistically significant as regards tumor multicentricity, vascular and lymphatic invasion, as well as lymph node metastasis.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Serpins / analysis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Thyroid Gland / chemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671538.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


38. Leinweber B, Chott A, Kerl H, Cerroni L: Epidermotropic precursor T-cell lymphoma with highly aggressive clinical behavior simulating localized pagetoid reticulosis. Am J Dermatopathol; 2007 Aug;29(4):392-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor cells expressed a T-phenotype (CD3+, CD20-) and were CD30-, CD4-, and CD8-negative.
  • A diagnosis of localized pagetoid reticulosis (Woringer-Kolopp disease) with possible large cell transformation was proposed.
  • Reevaluation of the skin lesion and of a tonsil specimen previously interpreted as benign hyperplasia showed features consistent with those observed in the lymph node.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Lymphatic Diseases / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Nipples / pathology. Paget's Disease, Mammary / pathology
  • [MeSH-minor] Adult. Antigens, CD3 / analysis. Antigens, CD43 / analysis. Antigens, CD7 / analysis. Fatal Outcome. Humans. Hyperplasia. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Palatine Tonsil / pathology. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667175.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD43; 0 / Antigens, CD7
  •  go-up   go-down


39. Rekhi B, Jambhekar NA: Morphologic spectrum, immunohistochemical analysis, and clinical features of a series of granular cell tumors of soft tissues: a study from a tertiary referral cancer center. Ann Diagn Pathol; 2010 Jun;14(3):162-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A granular cell tumor (GCT) is relatively uncommon and objectively diagnosed with neural markers on immunohistochemistry (IHC).
  • Herein, we present morphologic spectrum of 12 GCTs of soft tissues and skin, including 10 benign and 2 malignant subtypes with an optimal diagnostic IHC panel.
  • Six cases occurred in soft tissues and skin of extremities, 4 in the breast soft tissues, and 1 case each in the back and preauricular region, respectively.
  • On histopathology, all cases invariably revealed a nonencapsulated infiltrating tumor comprising groups and nests of granular cells with vesicular nuclei.
  • Immunohistochemistry in 10 cases (83.3%) showed diffuse S-100 positivity in all 7 benign and 2 malignant cases: cytoplasmic CD68 positivity (all 10 cases) and membranous vimentin staining (all 4 cases).
  • A GCT is a discrete tumor entity and can be identified from other granular lesions by its proximity to nerves and objective identification with diffuse S-100 positivity, CD68 positivity, and membranous vimentin positivity that form an optimal IHC panel in limited resource settings, irrespective of benign or malignant types.
  • [MeSH-major] Cancer Care Facilities. Granular Cell Tumor / pathology. Referral and Consultation. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / metabolism. Child. Female. Humans. Male. Middle Aged. S100 Proteins / metabolism. Vimentin / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20471560.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


40. Teo C, Broggi M: Surgical outcome of patients considered to have "inoperable" tumors by specialized pediatric neuro-oncological multidisciplinary teams. Childs Nerv Syst; 2010 Sep;26(9):1219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective study was conducted on all pediatric brain and spinal cord tumor patients operated in a single center from 1999 to 2009.
  • Details of preoperative treatment, diagnosis and clinical status, postoperative diagnosis, early and late outcomes, progression-free survival and overall survival, and parental satisfaction were reviewed.
  • In ten cases, radical removal of the tumor resulted in a change in histological diagnosis, usually from a presumed diagnosis of malignancy to a more benign variety (n = 6).
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2010 Sep;26(9):1227-8 [20574741.001]
  • [ErratumIn] Childs Nerv Syst. 2010 Dec;26(12):1833. Charles, Teo [corrected to Teo, Charles]; Morgan, Broggi [corrected to Broggi, Morgan]
  • [Cites] Curr Neurol Neurosci Rep. 2001 Mar;1(2):137-43 [11898509.001]
  • [Cites] Breast J. 2004 Sep-Oct;10(5):469-72 [15327510.001]
  • [Cites] BMJ. 1996 Jan 20;312(7024):145-8 [8563532.001]
  • [Cites] J Neurooncol. 2009 May;92(3):275-82 [19357955.001]
  • [Cites] Breast. 2006 Feb;15(1):119-22 [16473745.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):49-63 [15701282.001]
  • [Cites] BMJ. 1996 May 4;312(7039):1155-6 [8620140.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):979-85 [17047646.001]
  • [Cites] Oncologist. 2007 Jul;12(7):884-98 [17673619.001]
  • [Cites] Breast J. 2003 Jan-Feb;9(1):60-3 [12558678.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):274-82 [11452935.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2005 Jul;35(6):230-45 [15956960.001]
  • [Cites] Neurosurgery. 2004 Mar;54(3):553-63; discussion 563-5 [15028128.001]
  • [Cites] Cancer. 1978 Jan;41(1):29-35 [626937.001]
  • [Cites] Acta Neurochir (Wien). 2009 Feb;151(2):109-12 [19194651.001]
  • [Cites] Oncology (Williston Park). 2004 Sep;18(10):1263-8; discussion 1268-70, 1275 [15526830.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2480-91 [16904313.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):505-33 [10836005.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):160-6 [11307058.001]
  • [Cites] Pediatr Clin North Am. 1985 Jun;32(3):633-51 [3889800.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13):1649-61; discussion 1662, 1665-6, 1668 [15648297.001]
  • (PMID = 20563727.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Gu LQ, Li FY, Zhao L, Liu Y, Chu Q, Zang XX, Liu JM, Ning G, Zhao YJ: Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine; 2010 Oct;38(2):276-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this cross-sectional study, a total of 62 cases were examined, including 43 patients with PTCs and 19 with benign nodular goiters.
  • In logistic regression analysis, P2X7 receptor expression, tumor size, and capsular infiltration were predictors for lymph node metastasis (P=0.001).
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Female. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 2006 Mar;58(1):58-86 [16507883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7 [16916931.001]
  • [Cites] Endocr Rev. 2007 Dec;28(7):742-62 [17940185.001]
  • [Cites] Purinergic Signal. 2009 Sep;5(3):351-68 [19399640.001]
  • [Cites] Thyroid. 2009 Jan;19(1):21-5 [19072670.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1104-10 [11378340.001]
  • [Cites] J Endocrinol Invest. 2002 Dec;25(11):959-66 [12553555.001]
  • [Cites] Cancer Lett. 2010 Sep 1;295(1):110-23 [20236757.001]
  • [Cites] World J Surg. 2007 Nov;31(11):2085-91 [17885787.001]
  • [Cites] Endocrinology. 2008 Jan;149(1):389-96 [17947359.001]
  • [Cites] J Biol Chem. 2009 Apr 10;284(15):10120-8 [19204004.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):3877-83 [16547218.001]
  • [Cites] Histopathology. 2004 Mar;44(3):206-15 [14987223.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):695-8 [19017759.001]
  • [Cites] J Biol Chem. 2009 Dec 11;284(50):34553-60 [19854829.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Apoptosis. 2001 Aug;6(4):253-61 [11445667.001]
  • [Cites] Endocrinology. 2005 Jul;146(7):3172-8 [15790728.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Nature. 2009 Aug 20;460(7258):1035-9 [19626005.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11135-42 [11150303.001]
  • [Cites] Exp Cell Res. 2002 Oct 1;279(2):277-90 [12243753.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1518-22 [18324441.001]
  • [Cites] Biochem Pharmacol. 2009 Nov 1;78(9):1115-26 [19540829.001]
  • [Cites] Ann Diagn Pathol. 2007 Aug;11(4):235-40 [17630106.001]
  • [Cites] Hum Immunol. 2010 Aug;71(8):818-25 [20493226.001]
  • [Cites] Cancer Immunol Immunother. 2004 Sep;53(9):770-6 [15138717.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(1):1-10 [14997049.001]
  • [Cites] Mol Biol Rep. 2010 Apr;37(4):2037-42 [19649722.001]
  • [Cites] Exp Mol Pathol. 2004 Jun;76(3):253-9 [15126108.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):988-94 [17016456.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Dec;7(8):785-94 [18220537.001]
  • [Cites] Purinergic Signal. 2009 Jun;5(2):251-6 [19263244.001]
  • [Cites] Nephrol Dial Transplant. 2007 Feb;22(2):386-95 [17040997.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):907-14 [16424024.001]
  • [Cites] Endocr Pathol. 2010 Sep;21(3):149-53 [20506003.001]
  • [Cites] Science. 1996 May 3;272(5262):735-8 [8614837.001]
  • [Cites] J Neurochem. 2000 Sep;75(3):965-72 [10936177.001]
  • [Cites] Indian J Cancer. 2010 Apr-Jun;47(2):206-16 [20448388.001]
  • (PMID = 20972735.001).
  • [ISSN] 1559-0100
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Purinergic P2X7; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


42. Ohtsuka H: Chondrolipoma of the popliteal fossa and Japanese reports. J Dermatol; 2006 Mar;33(3):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients were male and five were female.
  • Two lesions each arose on the tongue, upper back and popliteal fossa, and one each on the buccal submucosa, shoulder, breast, lateral chest and sole.
  • The presented tumor was an early one because of the shortest duration and the smallest size in Japan.
  • Recent criteria for a benign mesenchymoma including a chondrolipoma were also described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620227.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 18
  •  go-up   go-down


43. Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S: Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol; 2007 Jan;177(1):359-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
  • PURPOSE: Because TRAIL (tumor necrosis factor related apoptosis inducing ligand) selectively kills cancer cells without damaging normal cells, a gene therapy approach using TRAIL is feasible for treating patients with cancer.
  • Our recent studies suggest that TRAIL receptor composition is the major modulator of TRAIL sensitivity, as demonstrated using prostate, breast and lung cancer cells.
  • MATERIALS AND METHODS: Paraffin embedded prostate tissues of 44 patients with benign prostatic hyperplasia, 28 with organ confined prostate carcinoma and 26 with advanced prostate carcinoma were analyzed using immunohistochemical staining procedures.
  • RESULTS: Significant levels of TRAIL-R4 decoy receptor expression were detected in patients with benign prostatic hyperplasia, and organ confined and advanced prostate carcinoma.
  • All TRAIL markers tested appear to be valuable markers for separating patients with benign prostatic hyperplasia from patients with organ confined prostate carcinoma or advanced prostate carcinoma.
  • [MeSH-minor] Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162091.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand
  •  go-up   go-down


44. Smarrito S, Salmon R: [Desmoid tumor in a male breast in the context of Gardner's syndrome. Case report]. Ann Chir; 2005 Jan;130(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumor in a male breast in the context of Gardner's syndrome. Case report].
  • [Transliterated title] Tumeur desmoïde du sein chez l'homme dans le cadre d'un syndrome de Gardner. A propos d'un cas.
  • Fibromatosis (Desmoid tumor) of the male breast is an exceptional location.
  • We present a case of such a tumor, in the context of Gardner's syndrome.
  • A palpable mass was discovered in the right breast of a 52 years old man, with a history of rectocolic adenomatous polyposis.
  • Mammography ant thoracic CT scan showed a stellar tumor, mimicking a breast cancer.
  • Treatment consisted of wide excision and histology revealed a desmoid tumor.
  • Desmoid tumors of the breast are benign lesions; they should be widely excised because of a high risk of recurrence.
  • Coloscopy is indicated in the presence of mammary fibromatosis, to look for associated multiple polyps, confirming the diagnosis of Gardner's syndrome.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / surgery. Fibromatosis, Aggressive / pathology. Fibromatosis, Aggressive / surgery. Gardner Syndrome / complications
  • [MeSH-minor] Colonoscopy. Humans. Male. Middle Aged. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664376.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


45. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T: Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol; 2010 Apr;32(2):90-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.
  • RESULTS: HSP47 and fascin were localized to cytoplasm, and HSP47 and fascin IR were higher in IDC and PCa than benign groups (p < 0.05).
  • Fascin expression correlated with estrogen receptor and progesterone receptor negativity, tumor size and stage in IDC and surgical margin status in PCa.
  • Although there is no relationship with recurrence or metastatic status, fascin overexpression correlated with tumor size, which may prompt its use as a prognostic factor in IDC.


46. Ahmed HG, Ali AS, Almobarak AO: Frequency of breast cancer among Sudanese patients with breast palpable lumps. Indian J Cancer; 2010 Jan-Mar;47(1):23-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of breast cancer among Sudanese patients with breast palpable lumps.
  • BACKGROUND: Breast cancer mortality is high in Sudan and most patients are detected at later stages of the disease due to the lack of awareness and absence of screening programs.
  • This study aimed to determine the pattern and frequency of breast cancer among patients presenting with palpable breast lumps within one year duration.
  • METHODS AND MATERIALS: We obtained information (patient's personal data) and Fine-Needle Aspiration (FNA) materials, for occurrence of 200 breast lesions in patients.
  • RESULTS: The diagnoses of the 200 breast lesions were as follows: 68 (34%) were malignant, 56 cases (28%) were fibroadenoma, 23 cases (11.5%) were fibrocystic change, 22 cases (11%) were inflammatory lesions (including mastitis and abscess formation), 12 cases (6%) were benign cysts and the remaining 19 patients (9.5%) were with lactation changes (8 cases), lipoma (6 cases), gynecomastia (3 cases) and phyllodes tumor (2 cases).
  • CONCLUSIONS: The frequency of advanced breast cancer among patients with breast lesions is high, in this subset of patients, which signals the urgency for implementation of breast screening programs.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Breast Diseases / diagnosis. Breast Diseases / epidemiology. Female. Humans. Male. Middle Aged. Sudan / epidemiology. Young Adult


47. Nabarra B, Pontoux C, Godard C, Osborne-Pellegrin M, Ezine S: Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice). Int J Exp Pathol; 2005 Dec;86(6):397-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the development of a carcinoma originating from thymic hyperplasia and followed by the formation of a benign tumour composed chiefly of medullary epithelial cells expressing the transgene and of lymphocytes, a pathology very rarely reported in mice.
  • [MeSH-major] Antigens, Polyomavirus Transforming / genetics. Antigens, Viral, Tumor / genetics. Neovascularization, Pathologic. Promoter Regions, Genetic. Pyruvate Kinase / genetics. Thymus Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Immunohistochemistry / methods. Male. Mice. Mice, Inbred CBA. Mice, Transgenic. Microscopy, Immunoelectron. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thymus. 1993 Aug;22(1):13-33 [7508157.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):409-16 [8123467.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2686-98 [8139568.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3979-83 [8171023.001]
  • [Cites] Prog Growth Factor Res. 1994;5(1):89-97 [7515293.001]
  • [Cites] Histopathology. 1994 Jul;25(1):21-9 [7959642.001]
  • [Cites] Int Rev Cytol. 1995;159:113-60 [7537724.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):127-37 [8534862.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] J Pathol. 1995 Nov;177(3):309-15 [8551394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5742-6 [8650163.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Metastasis Rev. 1995 Dec;14(4):263-77 [8821090.001]
  • [Cites] Cancer Lett. 1996 Oct 22;107(2):293-300 [8947527.001]
  • [Cites] Cell. 1997 Jun 13;89(6):981-90 [9200616.001]
  • [Cites] Science. 1997 Jul 4;277(5322):48-50 [9229772.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Lab Invest. 1990 Jun;62(6):690-6 [1694254.001]
  • [Cites] Lab Invest. 1990 Sep;63(3):298-306 [1697637.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1335-9 [1700664.001]
  • [Cites] Annu Rev Physiol. 1991;53:217-39 [1710435.001]
  • [Cites] Exp Pathol. 1990;40(4):301-12 [2098275.001]
  • [Cites] Eur J Cancer. 1991;27(6):781-5 [1712608.001]
  • [Cites] Virchows Arch. 1998 Jan;432(1):33-42 [9463585.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Dev Comp Immunol. 2001 Apr;25(3):231-43 [11164888.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):635-42 [12068292.001]
  • [Cites] Immunity. 2002 Jun;16(6):803-14 [12121662.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2842-5 [12218095.001]
  • [Cites] Mol Aspects Med. 2002 Dec;23(6S):S1-27 [12537983.001]
  • [Cites] Dev Immunol. 2002 Dec;9(4):223-31 [15144019.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2771-9 [1157049.001]
  • [Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]
  • [Cites] J Mol Biol. 1981 Dec 25;153(4):933-59 [6177862.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):500-7 [6182789.001]
  • [Cites] Cell. 1982 Sep;30(2):361-72 [6183000.001]
  • [Cites] Differentiation. 1983;23(3):256-69 [6189757.001]
  • [Cites] Pathol Res Pract. 1982;175(2-3):256-65 [6190148.001]
  • [Cites] Am J Pathol. 1984 Jan;114(1):121-30 [6197886.001]
  • [Cites] J Pathol. 1983 Nov;141(3):385-413 [6198502.001]
  • [Cites] Lab Invest. 1984 Jan;50(1):36-41 [6198559.001]
  • [Cites] Cell. 1984 Jun;37(2):367-79 [6327063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11822-7 [9751749.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1474-81 [9850173.001]
  • [Cites] Semin Diagn Pathol. 1999 Feb;16(1):2-17 [10355650.001]
  • [Cites] Pathology. 1998 May;30(2):111-22 [9643488.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7 [8356051.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5797-804 [6209004.001]
  • [Cites] Lab Invest. 1985 Jan;52(1):31-8 [2578201.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Mol Cell Biol. 1985 Apr;5(4):642-8 [2985963.001]
  • [Cites] J Natl Cancer Inst. 1985 Aug;75(2):369-79 [3860689.001]
  • [Cites] Nature. 1985 Aug 1-7;316(6027):457-60 [2991771.001]
  • [Cites] Lab Invest. 1986 Nov;55(5):521-30 [2430138.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] J Virol. 1987 Jun;61(6):2029-32 [3033329.001]
  • [Cites] Thymus. 1987;9(2):95-121 [3296336.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3178-84 [3118193.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2699-704 [2824189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(9):3135-9 [2452444.001]
  • [Cites] J Comp Pathol. 1988 Aug;99(2):187-203 [2846660.001]
  • [Cites] Toxicol Pathol. 1988;16(3):321-6 [3194653.001]
  • [Cites] Cell Tissue Res. 1988 Oct;254(1):225-31 [2461804.001]
  • [Cites] Oncogene Res. 1988;3(1):87-97 [3060799.001]
  • [Cites] Annu Rev Genet. 1988;22:479-519 [3071256.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cell. 1989 Sep 8;58(5):803-5 [2673531.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6108-17 [2551499.001]
  • [Cites] Am J Pathol. 1989 Oct;135(4):679-95 [2552813.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Am J Surg Pathol. 1990 Feb;14(2):151-66 [1689123.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Semin Immunol. 1990 Jan;2(1):13-24 [1717051.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1161-7 [1957168.001]
  • [Cites] J Clin Invest. 1992 Jan;89(1):244-53 [1729274.001]
  • [Cites] Mol Biol Cell. 1992 Feb;3(2):211-20 [1550962.001]
  • [Cites] Development. 1992 Feb;114(2):521-32 [1592003.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2175-87 [1279498.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):99-105 [7677978.001]
  • [Cites] Cancer Treat Res. 1992;63:359-71 [1284027.001]
  • [Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]
  • [Cites] FASEB J. 1993 Jul;7(10):866-71 [8344486.001]
  • [Cites] Toxicol Pathol. 1993;21(2):206-18 [8210943.001]
  • [Cites] Immunol Today. 1993 Sep;14(9):445-59 [8216723.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24 [8281615.001]
  • (PMID = 16309545.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Antigens, Viral, Tumor; 0 / Biomarkers, Tumor; EC 2.7.1.40 / Pyruvate Kinase
  • [Other-IDs] NLM/ PMC2517450
  •  go-up   go-down


48. Meaney PM, Fanning MW, di Florio-Alexander RM, Kaufman PA, Geimer SD, Zhou T, Paulsen KD: Microwave tomography in the context of complex breast cancer imaging. Conf Proc IEEE Eng Med Biol Soc; 2010;2010:3398-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microwave tomography in the context of complex breast cancer imaging.
  • The notion of applying microwave imaging to breast cancer imaging has been studied at various levels by numerous scientists.
  • The earliest appeal of this concept related to the presumably high property contrast between benign and malignant tissue that was unique to the breast.
  • Subsequent published studies have shown that this assumption was overly simplistic and that the tissue property heterogeneity is considerable within the breast.
  • As we have expanded the clinical use of our microwave tomographic system, we are now using this approach to monitor tumor progressions during neoadjuvant chemotherapy.
  • In these cases, while we can still characterize and track the tumor progression, we have observed a new phenomenon.
  • Very often these cancer patients exhibit skin thickening near the tumor site.
  • Our images have reconstructed elevated dielectric properties along the breast surface associated with the accompanying edema.
  • These observations further add to the complex nature of breast dielectric properties and the challenges for imaging them using microwave interrogation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IEEE Trans Med Imaging. 2001 Feb;20(2):104-16 [11321590.001]
  • [Cites] J Microw Power. 1981 Jun;16(2):107-19 [7033539.001]
  • [Cites] Magn Reson Med. 1991 Apr;18(2):371-83 [2046518.001]
  • [Cites] IEEE Trans Biomed Eng. 1995 Oct;42(10):1017-26 [8582719.001]
  • [Cites] Breast Cancer Res. 2013;15(2):R35 [23621959.001]
  • [Cites] Acad Radiol. 2007 Feb;14(2):207-18 [17236994.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Med Phys. 2007 Jun;34(6):2014-23 [17654905.001]
  • [Cites] Phys Med Biol. 2007 Oct 21;52(20):6093-115 [17921574.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Jun;18(6):496-507 [10463128.001]
  • (PMID = 21097245.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA080139; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / P01-CA080139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS512905; NLM/ PMC3757128
  •  go-up   go-down


49. Glazebrook KN, Reynolds CA: Mammary fibromatosis. AJR Am J Roentgenol; 2009 Sep;193(3):856-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Mammary fibromatosis is a rare, benign, nonmetastasizing stromal tumor.
  • It presents clinically and radiologically as a palpable, spiculated, and locally invasive tumor that is suspicious for malignancy.
  • Although histologically benign, the tumor is locally aggressive and has significant recurrence rates.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms, Male / diagnosis. Fibroma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696302.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Xu F, Liu B, Chen XY, Zhou EX, Fan DF, Ma Y, Tang ZH: [Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Feb;11(2):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases].
  • OBJECTIVE: To explore the clinical characteristics, diagnosis and therapy of thyroid carcinoma in children.
  • RESULTS: A hard thyroid mass was observed in 10 out of 12 children with thyroid carcinoma, but only one out of 15 children with benign thyroid tumor (<0.05).
  • The rate of cervical lymph node metastasis in children with thyroid carcinoma was significantly higher than that in children with benign thyroid tumor (<0.05).
  • A combination of ultrasonography and CT is helpful to the diagnosis of childhood thyroid carcinoma.
  • [MeSH-major] Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Female. Follow-Up Studies. Humans. Iodine Radioisotopes / therapeutic use. Male. Postoperative Complications / etiology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222949.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


51. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Only 5 (36%) of the 14 benign tumors occurred in the RT field, with osteochondroma being the most common.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Radiation Dosage. Retrospective Studies. Survival Rate


52. Kornasiewicz O, Debski M, Stepnowska M, Szałas A, Bar-Andziak E, Krawczyk M: The enzymatic activity of type 1 iodothyronine deiodinase (D1) is low in liver hemangioma: a preliminary study. Arch Immunol Ther Exp (Warsz); 2010 Feb;58(1):77-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There has been strong evidence that the metabolism of thyroid hormones is disturbed in some neoplastic tissues such as thyroid, renal, and breast cancer.
  • However, there are few available data about D1 enzyme activity in benign tumors such as hemangioma, which is the most common primary liver tumor.
  • These finding demonstrate a low enzymatic activity of D1 in liver hemangioma and suggest an as yet unknown role of thyroid hormones in this type of benign liver tumor.
  • [MeSH-minor] Adult. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2002 Feb;23(1):38-89 [11844744.001]
  • [Cites] Eur J Endocrinol. 2002 Apr;146(4):559-66 [11916626.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jun;56(6):735-43 [12072042.001]
  • [Cites] Eur J Endocrinol. 2002 Aug;147(2):263-8 [12153750.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1384-8 [12629133.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):121-32 [12668276.001]
  • [Cites] Mol Cell Endocrinol. 2003 Mar 28;201(1-2):25-31 [12706290.001]
  • [Cites] Monaldi Arch Chest Dis. 2003 Apr-Jun;59(2):140-5 [14635503.001]
  • [Cites] Pediatrics. 2003 Dec;112(6 Pt 1):1424-6 [14654623.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):791-8 [8077363.001]
  • [Cites] Endocrinology. 1996 Aug;137(8):3308-15 [8754756.001]
  • [Cites] Thyroid. 2005 Mar;15(3):210-21 [15785240.001]
  • [Cites] J Pediatr Endocrinol Metab. 2005 May;18(5):511-4 [15921182.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Jun;62(6):672-8 [15943828.001]
  • [Cites] Thyroid. 2005 Aug;15(8):875-81 [16131330.001]
  • [Cites] J Clin Invest. 2005 Sep;115(9):2524-33 [16127464.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1137-46 [16279847.001]
  • [Cites] Mol Endocrinol. 2005 Dec;19(12):3126-36 [16037131.001]
  • [Cites] J Vasc Res. 2006;43(6):522-32 [17008795.001]
  • [Cites] Thyroid. 2007 Jan;17(1):3-10 [17274741.001]
  • [Cites] J Endocrinol Invest. 2001 Apr;24(4):253-61 [11383912.001]
  • (PMID = 20049650.001).
  • [ISSN] 1661-4917
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 1.11.1.- / iodothyronine deiodinase type I; EC 1.11.1.8 / Iodide Peroxidase
  • [Other-IDs] NLM/ PMC2816262
  •  go-up   go-down


53. Blanco-Aparicio C, Cañamero M, Cecilia Y, Pequeño B, Renner O, Ferrer I, Carnero A: Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One; 2010;5(2):e9305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated expression of AKT has been noted in a significant percentage of primary human breast cancers, mainly as a consequence of the PTEN/PI3K pathway deregulation.
  • To investigate the mechanistic basis of the AKT gain of function-dependent mechanisms of breast tumorigenesis, we explored the phenotype induced by activated AKT transgenes in a quantitative manner.
  • Finally, we analyzed the impact that a possible senescent checkpoint might have in the tumor promotion inhibition observed, crossing these lines to mammary specific p53(R172H) mutant expression, and to p27 knock-out mice.
  • We analyzed the benign, premalignant and malignant lesions extensively by pathology and at molecular level analysing the expression of proteins involved in the PI3K/AKT pathway and in cellular senescence.
  • Finally, our work shows that levels of activated AKT are not essential in the induction of benign or premalignant tumors, or in the cooperation of AKT with other tumorigenic signal such as mutant p53, once AKT pathway is activated, the relative level of activity seems not to determine the phenotype.
  • [MeSH-minor] Animals. Blotting, Western. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Transgenic. Phosphorylation. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


54. Waldmann J, Feldmann G, Slater EP, Langer P, Buchholz M, Ramaswamy A, Saeger W, Rothmund M, Fendrich V: Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer; 2008 Dec 2;99(11):1900-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Snail expression was neither detected in normal adrenocortical tissue, nor in benign adrenocortical adenomas.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers, Tumor / analysis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Cadherins / biosynthesis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Horm Res. 1997;47(4-6):279-83 [9167965.001]
  • [Cites] Physiol Rev. 1959 Jan;39(1):162-82 [13623432.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):252-8 [15668718.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):42-6 [15712635.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):772-6 [15917668.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7622-7 [16140927.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):65-71 [16786124.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jun;36(6):357-63 [16766568.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5395-402 [17000672.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Breast Cancer Res. 2006;8(4):105 [16834762.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Histopathology. 2007 Aug;51(2):239-45 [17593212.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):865-74 [17914115.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1267-78 [11430829.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):78-84 [15272533.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Endocrinology. 1990 Jun;126(6):3251-62 [2161753.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1303-9 [9137490.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):421-5 [9694573.001]
  • (PMID = 19018264.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2600683
  •  go-up   go-down


55. Brown B, Ram A, Clayton P, Humphrey G: Conservative management of bilateral Sertoli cell tumors of the testicle in association with the Carney complex: a case report. J Pediatr Surg; 2007 Sep;42(9):E13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large cell calcifying Sertoli cell tumor of the testicle is a rare, hormonally active sex cord-stromal tumor seen in patients with Carney complex.
  • The availability of specific antiestrogen drugs means that bilateral orchiectomy for this benign tumor may no longer be warranted.
  • Approximately two thirds of teenaged boys will develop some degree of breast enlargement that spontaneously regresses as testosterone levels rise (Ill Med J 1938;73:113).
  • Disorders of the breast.
  • [MeSH-major] Multiple Endocrine Neoplasia / diagnosis. Sertoli Cell Tumor / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Child. Gynecomastia / complications. Gynecomastia / therapy. Humans. Male

  • Genetic Alliance. consumer health - Carney Complex.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848226.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Mohri Y, Mohri T, Wei W, Qi YJ, Martin A, Miki C, Kusunoki M, Ward DG, Johnson PJ: Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br J Cancer; 2009 Jul 21;101(2):295-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI) and antibody arrays were used to compare protein expression in 21 pairs of gastric cancer tissue and adjacent normal mucosa and serum from 51 gastric cancer patients and 29 patients with benign gastric diseases.
  • Macrophage migration inhibitory factor (MIF) was increased five-fold (P=1.84 x 10(-7)) in the serum of gastric cancer patients relative to individuals with benign gastric disease.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2001 Jan;32(1):41-4 [11154168.001]
  • [Cites] Scand J Gastroenterol. 2000 Sep;35(9):950-6 [11063155.001]
  • [Cites] Eur J Clin Invest. 2001 Apr;31(4):337-43 [11298781.001]
  • [Cites] Cancer Lett. 2001 Oct 10;171(2):125-32 [11520595.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):318-22 [11553862.001]
  • [Cites] Helicobacter. 2001 Sep;6(3):216-24 [11683924.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1061-6 [11668338.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):298-304 [11919217.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1311-24 [11943716.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):735-9 [12738449.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9354-9 [12878730.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6971-83 [14583499.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):139-44 [14693236.001]
  • [Cites] Am J Clin Pathol. 2008 May;129(5):772-9 [18426738.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7338-48 [18490733.001]
  • [Cites] Pathol Oncol Res. 2008 Mar;14(1):79-83 [18347935.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R48 [18510725.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:42-7 [15335412.001]
  • [Cites] Oncology. 1999 Jul;57(1):55-62 [10394126.001]
  • [Cites] Gastric Cancer. 2004;7(4):233-9 [15616771.001]
  • [Cites] BMC Cancer. 2005 Jan 19;5:8 [15656915.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1485-503 [16285950.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] Gut. 2006 Jun;55(6):797-802 [16488898.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1898-905 [16755300.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Lett. 2008 Mar 18;261(2):147-57 [18171602.001]
  • [Cites] J Exp Med. 1999 Nov 15;190(10):1375-82 [10562313.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):16-9 [11248169.001]
  • (PMID = 19550422.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Macrophage Migration-Inhibitory Factors; 0 / Neoplasm Proteins; 0 / alpha-Defensins; 0 / human neutrophil peptide 1; 0 / human neutrophil peptide 2; 0 / human neutrophil peptide 3
  • [Other-IDs] NLM/ PMC2720195
  •  go-up   go-down


57. Meguerditchian AN, Malik DA, Hicks DG, Kulkarni S: Solitary fibrous tumor of the breast and mammary myofibroblastoma: the same lesion? Breast J; 2008 May-Jun;14(3):287-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the breast and mammary myofibroblastoma: the same lesion?
  • Benign stromal tumors of the breast are rare mesenchymal neoplasms that have significant clinical and morphologic overlap.
  • We report the case of a spindle cell tumor occurring in the mammary gland with mixed features of solitary fibrous tumor and mammary myofibroblastoma.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Neoplasms, Muscle Tissue / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Aged. Humans. Male

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384484.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


58. Abdel Salam I, Gaballa HE, Abdel Wahab N: Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med Oncol; 2009;26(2):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 30 patients with pathologically proven NSCLC were enrolled in this study in addition to ten normal controls subjects and ten cases with benign pulmonary diseases as broncheicatsis, chronic obstructive pulmonary disease.
  • The levels were significantly higher in those with stages III, IV compared with I, II, and in those with higher grades of the tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / blood. Receptor, ErbB-2 / blood
  • [MeSH-minor] Aged. Bronchoalveolar Lavage Fluid / chemistry. Female. Humans. Male. Middle Aged. Prognosis


59. Ewan King L, Li X, Cheikh Saad Bouh K, Pedneault M, Chu CW: Human kallikrein 10 ELISA development and validation in breast cancer sera. Clin Biochem; 2007 Sep;40(13-14):1057-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 10 ELISA development and validation in breast cancer sera.
  • There is significant interest in measuring hK10 which may act as a tumor suppressor in some cancers.
  • We have developed an ELISA for hK10 and determined its analytical and clinical performance in normal and breast cancer sera.
  • The assay was analytically validated and used to determine serum levels of hK10 in a set of breast cancer, benign breast disease and normal samples.
  • Concentrations were not age related and were not significantly different from benign fibrocystic disease or breast cancer.
  • However, in a subset of breast cancer patients with both early and late stage disease, serum hK10 levels were elevated, at >1.55 ng/mL, above all normal female and benign disease samples.
  • CONCLUSIONS: We report in detail the analytical performance of a colorimetric hK10 ELISA validated in human serum and report for the first time the hK10 serum concentration in benign and breast cancer samples.
  • [MeSH-major] Breast Neoplasms / blood. Enzyme-Linked Immunosorbent Assay / methods. Kallikreins / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585892.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.- / KLK10 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


60. Kammori M, Izumiyama N, Nakamura K, Kurabayashi R, Kashio M, Aida J, Poon SS, Kaminishi M: Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization. Oncology; 2006;71(5-6):430-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization.
  • In conclusion, our TCR method can be used to distinguish between benign and malignant tissue in esophageal lesions.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Esophageal Neoplasms / diagnosis. Esophagus / pathology. In Situ Hybridization, Fluorescence / methods. Telomere / genetics
  • [MeSH-minor] Aged. Anaphase / genetics. Biomarkers, Tumor / biosynthesis. Centromere / pathology. Chromosomal Instability / genetics. Humans. Male. Middle Aged. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17878747.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Yang DM, Kim HC, Lim JW, Jin W, Ryu CW, Kim GY, Cho H: Sonographic findings of groin masses. J Ultrasound Med; 2007 May;26(5):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common benign tumor of the inguinal region was a lipoma.
  • Other benign tumors of the groin included leiomyomas, dermoid cysts, epidermoid cysts, and lymphangiomas.
  • Secondary malignant tumors of the inguinal regions were metastatic lymphomas and metastatic carcinomas of the lung, breast, ovary, and gastrointestinal tract.
  • CONCLUSIONS: Although there was substantial overlap of sonographic findings in the various inguinal masses, clinical history and certain sonographic details can assist in making the correct diagnosis.
  • [MeSH-minor] Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460003.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • L1 was absent in breast carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


63. Pontes ER, Matos LC, da Silva EA, Xavier LS, Diaz BL, Small IA, Reis EM, Verjovski-Almeida S, Barcinski MA, Gimba ER: Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3. Prostate; 2006 Oct 1;66(14):1463-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Here we evaluate auto-antibody response against two potential antigenic determinants of genes highly expressed in low Gleason Score prostate cancer (PC) tumor samples, namely FLJ23438 and VAMP3.
  • The auto-antibody response against FLJ23438 and VAMP3 recombinant proteins was tested by immunoblot assays using PC, benign prostate hyperplasia (BPH), healthy donors (HD), and other human cancers plasma samples.
  • [MeSH-major] Adenocarcinoma / immunology. Autoantibodies / blood. Biomarkers, Tumor / immunology. Prostatic Neoplasms / immunology. Vesicle-Associated Membrane Protein 3 / immunology
  • [MeSH-minor] Aged. Antigens / genetics. Antigens / immunology. Breast Neoplasms. Carcinoma, Squamous Cell. Cell Line, Tumor. Colorectal Neoplasms. Esophageal Neoplasms. Gene Expression Regulation, Neoplastic. Humans. Lung Neoplasms. Male. Middle Aged. Open Reading Frames / genetics. Prostatic Hyperplasia / epidemiology. Prostatic Hyperplasia / immunology. Prostatic Hyperplasia / physiopathology. RNA, Messenger / genetics. RNA, Small Nuclear / genetics. RNA, Small Nuclear / immunology. Recombinant Proteins / genetics. Recombinant Proteins / immunology. Seroepidemiologic Studies

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16897729.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Small Nuclear; 0 / Recombinant Proteins; 0 / U2 small nuclear RNA; 0 / VAMP3 protein, human; 0 / Vesicle-Associated Membrane Protein 3
  •  go-up   go-down


64. Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D: Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat; 2007 Oct;105(2):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
  • BACKGROUND: Male breast cancer (MBC) commonly expresses hormone receptors and there is anecdotal evidence of disease responsivity to aromatase inhibitors in the metastatic setting.
  • Specimens were reviewed for standard pathologic characteristics and tumor blocks were incorporated into three TMA's (four 1 mm cores per tumor).
  • ITA staining intensity was compared to control, benign hepatic tissue and if greater than or equal to liver was scored positive and if less than liver was scored negative.
  • Median tumor size was 2.6 cm (0.3-8.0 cm) and 22(41%) had nodal metastases.
  • [MeSH-major] Aromatase / metabolism. Breast Neoplasms, Male / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Humans. Immunoenzyme Techniques. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Survival Rate. Tissue Array Analysis


65. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM: Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol; 2007 Mar;20(3):375-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant expression of human leukocyte antigen G (HLA-G) has been proposed to be involved in tumor escape mechanisms.
  • It has been also proposed that detection of HLA-G might service as a potential biomarker for diagnosis or prediction of the clinical outcomes in ovarian and breast cancers, carcinoma of the lung and endometrial cancer.
  • In this prospectively study, HLA-G protein expression was observed in 64.6% (130/201) of the primary site colorectal carcinomas, but not in the normal colorectal tissues or benign adenomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis
  • [MeSH-minor] Female. HLA-G Antigens. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277760.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


66. Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, Levy R, Lossos IS, Natkunam Y: The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol; 2009 Feb;131(2):264-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor LMO2 is involved in vascular and hematopoietic development and hematolymphoid neoplasia.
  • LMO2 reactivity is otherwise virtually absent in nonhematolymphoid tissues except in breast myoepithelium, prostatic basal cells, and secretory phase endometrial glands.
  • LMO2 is uniformly expressed in benign vascular and lymphatic neoplasms and in most malignant vascular neoplasms with the exception of epithelioid vascular neoplasms of pleura and bone.
  • Among nonvascular neoplasms, LMO2 reactivity is present in giant cell tumor of tendon sheath, juvenile xanthogranuloma, a subset of gastrointestinal stromal tumors, small round blue cell tumors, and myoepithelial-derived neoplasms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141387.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA34233; United States / NCI NIH HHS / CA / CA122105; United States / NCI NIH HHS / CA / CA33399; United States / NCI NIH HHS / CA / R37 CA033399; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105; United States / NCI NIH HHS / CA / CA109335; United States / NCI NIH HHS / CA / P30 CA124435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ NIHMS636776; NLM/ PMC4305438
  •  go-up   go-down


67. Zhou XD, Sens MA, Garrett SH, Somji S, Park S, Gurel V, Sens DA: Enhanced expression of metallothionein isoform 3 protein in tumor heterotransplants derived from As+3- and Cd+2-transformed human urothelial cells. Toxicol Sci; 2006 Oct;93(2):322-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of metallothionein isoform 3 protein in tumor heterotransplants derived from As+3- and Cd+2-transformed human urothelial cells.
  • Immunohistochemical staining of MT-3 on archival diagnostic specimens showed that only 2 of 63 (3.17%) benign bladder specimens had even weak reactivity for the MT-3 protein.
  • The gain in MT-3 expression when cells were grown as heterotransplants was also shown to occur for the MCF-7, T-47D, Hs 578t, MDA-MB-231 breast cancer, and the PC-3 prostate cancer cell lines.
  • [MeSH-minor] Animals. Biomarkers, Tumor. Breast Neoplasms / metabolism. Cells, Cultured. Female. Humans. Immunohistochemistry. Male. Mice. Neoplasm Transplantation. Prostatic Neoplasms / metabolism. Protein Isoforms. RNA, Messenger / analysis. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854967.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094997; United States / NCI NIH HHS / CA / R01 CA098832
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / RNA, Messenger; 00BH33GNGH / Cadmium; 9038-94-2 / Metallothionein; N712M78A8G / Arsenic
  •  go-up   go-down


68. Chen L, Madura K: Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res; 2005 Jul 1;65(13):5599-606
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
  • The activation of this pathway in various cancers and malignancies has been described, and several genetic determinants of breast cancer, including BRCA1 and BRCA2, are linked to protein degradation.
  • To investigate the involvement of the Ub/proteasome system in breast cancer, we examined a collection of 25 patient-matched breast cancer and normal adjacent tissues and detected activation of numerous components of the Ub/proteasome pathway.
  • The activity of the proteasome, and levels of proteasome subunits and various targeting factors, were increased in >90% of primary breast cancer tissue specimens.
  • In contrast, no activation was observed in benign solid tumors, indicating that the response is specific to abnormal growth in neoplastic cells.
  • Additionally, the accumulation of high levels of certain Ub-conjugating enzymes (UbcH1, UbcH2, and UbcH5), was specific to breast cancer, as no change in abundance was detected in primary colon cancer tissue extracts.
  • Surprisingly, the Ub/proteasome system was not activated in a well-characterized cell culture-based breast cancer model system.
  • Collectively, these findings suggest that the analysis of primary breast cancer tissue samples will be indispensable for the biochemical characterization of neoplastic growth and for the development of therapeutics.
  • [MeSH-major] Breast Neoplasms / enzymology. Peptide Elongation Factor 1 / metabolism. Proteasome Endopeptidase Complex / metabolism. Ubiquitin-Conjugating Enzymes / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Tumor Cells, Cultured. Ubiquitin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994932.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83875
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Elongation Factor 1; 0 / Ubiquitin; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  •  go-up   go-down


69. Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J: [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation]. J Radiol; 2009 Sep;90(9 Pt 1):1067-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Rétraction capsulaire hépatique en regard d'une lésion circonscrite: à propos de 26 patients avec preuve histologique.
  • PURPOSE: To review the histological features of 26 circumscribed liver lesions associated with liver capsule retraction and discuss the differential diagnosis while evaluating for the presence of fibrous stromal reaction.
  • RESULTS: Twenty-one patients had benign or malignant liver tumors and 5 patients had confluent hepatic fibrosis.
  • Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1), breast carcinoma (n=1), gallbladder carcinoma (1) and endocrine neoplasm of the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
  • In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2009 Sep;90(9 Pt 1):1019-20 [19752803.001]
  • (PMID = 19752810.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


70. Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME: GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate; 2006 Jun 1;66(8):886-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gene regulated in breast cancer 1 (GREB1) is a novel estrogen-regulated gene shown to play a pivotal role in hormone-stimulated breast cancer growth.
  • RESULTS: Real-time PCR demonstrated high level GREB1 expression in benign prostatic hypertrophy (BPH), localized prostate cancer (L-PCa), and hormone refractory prostate cancer (HR-PCa).
  • [MeSH-major] Androgens / pharmacology. Cell Proliferation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Prostatic Neoplasms / genetics. Prostatic Neoplasms / physiopathology
  • [MeSH-minor] Cell Line, Tumor. Chromatin Immunoprecipitation. DNA, Neoplasm / drug effects. DNA, Neoplasm / genetics. Dose-Response Relationship, Drug. Estrogens / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Neoplasms, Hormone-Dependent / chemistry. Neoplasms, Hormone-Dependent / genetics. Neoplasms, Hormone-Dependent / pathology. Neoplasms, Hormone-Dependent / physiopathology. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis. RNA, Messenger / genetics. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496412.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA069568
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / DNA, Neoplasm; 0 / Estrogens; 0 / GREB1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down


71. Gerszten PC, Burton SA: Clinical assessment of stereotactic IGRT: spinal radiosurgery. Med Dosim; 2008;33(2):107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At our institution, we have developed a successful multidisciplinary spinal radiosurgery program in which 542 spinal lesions (486 malignant and 56 benign lesions) were treated with a single-fraction radiosurgery technique.
  • The most common metastatic tumors were renal cell (89 cases), breast (74 cases), and lung (71 cases).
  • The most common benign tumors were neurofibroma (24 cases), schwannoma (13 cases), and meningioma (7 cases).
  • Tumor volume ranged from 0.16 to 298 mL (mean 47 mL).
  • The primary indication for radiosurgery was pain in 326 cases, as a primary treatment modality in 70 cases, for tumor radiographic tumor progression in 65 cases, for post-surgical treatment in 38 cases, for progressive neurological deficit in 35 cases, and as a radiation boost in 8 cases.
  • Long-term tumor control was demonstrated in 90% of lesions treated with radiosurgery as a primary treatment modality and in 88% of lesions treated for radiographic tumor progression.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Equipment Design. Female. Humans. Male. Middle Aged. Stereotaxic Techniques. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18456162.001).
  • [ISSN] 0958-3947
  • [Journal-full-title] Medical dosimetry : official journal of the American Association of Medical Dosimetrists
  • [ISO-abbreviation] Med Dosim
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Misra S, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem; 2006 Nov 17;281(46):34936-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyaluronan (HA) is enriched in the pericellular matrices of many malignant human tumors, and manipulations of HA interactions have strong effects on tumor progression in animal models.
  • On the other hand, inhibition of constitutive HA-tumor cell interactions in malignant cells inhibits these properties.
  • IGF1R-beta, PDGFR-beta, EGFR and c-MET, in colon, prostate, and breast carcinoma cells.
  • On the other hand, we show that these RTKs are activated in phenotypically normal or relatively benign tumor cells by experimentally increasing HA production.
  • [MeSH-minor] Breast Neoplasms / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Female. Humans. Male. Prostatic Neoplasms / metabolism. Signal Transduction


73. Nonn L, Ananthanarayanan V, Gann PH: Evidence for field cancerization of the prostate. Prostate; 2009 Sep 15;69(13):1470-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to comparing cancer-adjacent benign tissue to more distant areas or to "supernormal" tissue from cancer-free organs, investigators can use a nested case-control design for negative biopsies that offers a number of unique advantages.
  • CONCLUSIONS: True carcinogenic field effects should be distinguished from secondary responses of the microenvironment to a developing tumor, although the latter may still lead to useful clinical prediction tools.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Jun 1;99(4):549-54 [11992544.001]
  • [Cites] BJU Int. 2008 Aug;102(3):364-70 [18410440.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6405-9 [12438224.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):1978-87 [12673203.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5401-6 [12702759.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):540-52 [14755684.001]
  • [Cites] J Urol. 2004 Apr;171(4):1419-23 [15017188.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3465-73 [15161703.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11428-31 [15280533.001]
  • [Cites] Mol Cancer Res. 2004 Sep;2(9):489-94 [15383627.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6572-8 [15475446.001]
  • [Cites] Cancer. 1995 May 15;75(10):2545-51 [7537624.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):824-8 [7635445.001]
  • [Cites] Tumour Biol. 1996;17(1):58-64 [7501974.001]
  • [Cites] Eur Urol. 1996;30(2):191-200 [8875200.001]
  • [Cites] Hum Pathol. 1997 Feb;28(2):143-8 [9023393.001]
  • [Cites] J Pathol. 1997 Aug;182(4):442-9 [9306966.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] J Urol. 1998 Oct;160(4):1533-9 [9751408.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1995-2002 [9806659.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5835-41 [9865743.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Feb;24(2):127-34 [9885979.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):569-76 [10100708.001]
  • [Cites] Prostate. 1999 Sep 15;41(1):12-9 [10440871.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4784-7 [10519384.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] J Pathol Bacteriol. 1954 Oct;68(2):617-21 [14354565.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4097-100 [15899799.001]
  • [Cites] J Mol Histol. 2005 Mar;36(3):159-65 [15900405.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] BMC Cancer. 2005;5:45 [15892885.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(11):1372-80 [11435067.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8617-23 [11751373.001]
  • [Cites] J Urol. 2005 Aug;174(2):514-8 [16006883.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19093-6 [16361440.001]
  • [Cites] Mol Cancer Res. 2006 Jan;4(1):1-8 [16446401.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):317-22 [16604550.001]
  • [Cites] BMC Cancer. 2006;6:73 [16545117.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1082-7 [16557596.001]
  • [Cites] J Mol Diagn. 2006 Jul;8(3):312-9 [16825503.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Nov;6(6):803-9 [17140367.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] Prostate. 2007 May 1;67(6):638-44 [17342751.001]
  • [Cites] J Urol. 2007 May;177(5):1736-40 [17437801.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):657-66 [17875519.001]
  • [Cites] Breast Cancer Res Treat. 2007 Nov;106(1):75-84 [17221152.001]
  • [Cites] Mod Pathol. 2007 Nov;20(11):1121-7 [17873893.001]
  • [Cites] Prostate. 2008 Feb 1;68(2):152-60 [18058812.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):67-75 [18065961.001]
  • [Cites] BJU Int. 2008 Mar;101(6):765-74 [18190638.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3380-5 [18519767.001]
  • [Cites] PLoS One. 2008;3(10):e3617 [18974881.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1714-20 [20177031.001]
  • [Cites] J Invest Dermatol. 2002 Aug;119(2):522-6 [12190879.001]
  • (PMID = 19462462.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090759; United States / NCI NIH HHS / CA / R03 CA131595; United States / NCI NIH HHS / CA / R01 CA90759
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers
  • [Number-of-references] 59
  • [Other-IDs] NLM/ NIHMS482768; NLM/ PMC3690597
  •  go-up   go-down


74. Chou SH, Tseleni-Balafouta S, Moon HS, Chamberland JP, Liu X, Kavantzas N, Mantzoros CS: Adiponectin receptor expression in human malignant tissues. Horm Cancer; 2010 Jun;1(3):136-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no difference in the expression of adiponectin receptors or their mRNA between malignant and benign kidney tissue specimens.
  • Overall, there were no correlations between expression of adiponectin receptors or their mRNA and tumor prognostic factors.
  • [MeSH-minor] Adult. Aged. Blotting, Western. Carcinoma, Renal Cell / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Male. Middle Aged. Obesity / complications. Obesity / metabolism. RNA, Messenger / analysis. Real-Time Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s858-66 [18265479.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):275-81 [18979105.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [14983034.001]
  • [Cites] Oncology. 2007;73(3-4):261-9 [18424891.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Int J Oncol. 2009 Feb;34(2):339-44 [19148467.001]
  • [Cites] Dig Dis Sci. 2008 Mar;53(3):597-605 [17763959.001]
  • [Cites] Cancer Lett. 2010 Feb 28;288(2):177-82 [19646806.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Endocrinology. 2010 Jan;151(1):115-22 [19887569.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Jpn J Clin Oncol. 2008 Feb;38(2):106-11 [18245516.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):79-87 [15936715.001]
  • [Cites] Breast Cancer Res Treat. 2008 Dec;112(3):405-10 [18163210.001]
  • [Cites] Maturitas. 2009 Jul 20;63(3):253-6 [19524379.001]
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):555-61 [8406981.001]
  • [Cites] Clin Sci (Lond). 2002 Aug;103(2):137-42 [12149104.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):395-403 [12884914.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):43-50 [18313838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Obstet Gynecol Surv. 2005 Oct;60(10):683-92 [16186785.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6365-78 [15322511.001]
  • [Cites] Obesity (Silver Spring). 2006 Jan;14(1):28-35 [16493120.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8 [17192291.001]
  • [Cites] Trends Pharmacol Sci. 2005 Feb;26(2):69-76 [15681023.001]
  • [Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1430-6 [17512191.001]
  • [Cites] Oncol Rep. 2008 Oct;20(4):971-7 [18813842.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18341-7 [15734737.001]
  • [Cites] Int J Hematol. 2008 Nov;88(4):374-80 [18818986.001]
  • [Cites] J Clin Pathol. 2009 Aug;62(8):705-9 [19638541.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):140-6 [17036323.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):289-99 [18310295.001]
  • [Cites] BMJ. 2007 Dec 1;335(7630):1134 [17986716.001]
  • [Cites] Eur Urol. 2008 Oct;54(4):866-73 [18343565.001]
  • [Cites] Int J Obes (Lond). 2007 Dec;31(12):1843-8 [17607322.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1573-8 [17205522.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3 [15001602.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3321-7 [19661351.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):432-6 [8621222.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):814-21 [12910527.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Gut. 2008 Nov;57(11):1531-8 [18676419.001]
  • [Cites] Lung Cancer. 2008 Sep;61(3):391-7 [18342391.001]
  • [Cites] Cancer Causes Control. 2009 Jul;20(5):625-33 [19051043.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):308-13 [17301264.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1214-21 [18483344.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1120-7 [17459059.001]
  • (PMID = 21761356.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Adiponectin
  •  go-up   go-down


75. Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E, Czerwenka K: Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep; 2006 Feb;15(2):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Protein expression was, however, considerably less frequent in normal breast (18%), lung (16%) and ovarian (12%) tissues.
  • In contrast to their corresponding benign tissues, pCrkL expression was significantly more common in breast cancer samples (49%, p<0.0001; Fisher's exact test), lung carcinomas (55%, p=0.0002), lymphatic tissues (80% vs. 10%, p=0.012), skin cancer (67%, p=0.020), ovarian malignomas (50%, p<0.0001) and colon carcinomas (63%, p<0.03).
  • We hypothesize that pCrkL is selectively up-regulated in a number of malignant tumor entities and involved in malignant transformation.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Biomarkers, Tumor / analysis. Neoplasms / drug therapy. Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / drug effects
  • [MeSH-minor] Benzamides. Blotting, Western. Cell Line, Tumor. Enzyme Activation / drug effects. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Up-Regulation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391854.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / CRKL protein; 0 / Nuclear Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


76. Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G: The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol; 2009 Jan-Feb;27(1):53-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To improve treatment for patients with breast and prostate cancer.
  • Aromatase (estrogen synthetase) inhibitors have now been extensively tested in clinical trials in breast cancer patients.
  • Inhibitors of aromatase (AIs) are showing greater benefit than antiestrogens in the treatment of breast cancer.
  • Although effective in other conditions in both women and men, AIs have not been useful in benign prostatic hypertrophy or prostate cancer.
  • Analysis of breast tumors from mice treated with letrozole revealed up-regulation of HER-2 and MAP Kinase signaling proteins and down-regulation of the estrogen receptor.
  • When mice bearing resistant tumors were treated with trastuzumab, the anti-HER-2 antibody (herceptin), HER-2 was decreased in the tumor but the estrogen receptor and aromatase were restored.
  • Tumor growth was significantly inhibited by treatment with trastuzumab in addition to letrozole.
  • CONCLUSIONS: Aromatase inhibitors are proving to be an effective new class of agents for the treatment of breast cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Steroids. 1987 Oct-Dec;50(4-6):523-36 [3332939.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):622-30 [10574247.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):461-8 [2465302.001]
  • [Cites] N Engl J Med. 1989 Aug 17;321(7):419-24 [2503724.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6551-5 [2479464.001]
  • [Cites] Biol Reprod. 1989 Nov;41(5):889-98 [2696557.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6949-54 [2208160.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Oct;73(4):717-26 [1890148.001]
  • [Cites] Ann Med. 1991 Aug;23(3):201-3 [1718322.001]
  • [Cites] Gynecol Endocrinol. 1992 Mar;6(1):13-7 [1580162.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jun;74(6):1247-52 [1592866.001]
  • [Cites] Cancer. 1993 Feb 1;71(3 Suppl):1059-67 [8428328.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):321-30 [8476746.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Apr;45(4):217-25 [8499330.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2861-4 [8187068.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:195-211 [7598491.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3073-7 [7606729.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Endocrinology. 1996 Jul;137(7):3061-8 [8770932.001]
  • [Cites] Prostate. 1996 Sep;29(3):153-8 [8827083.001]
  • [Cites] J Urol. 1997 Apr;157(4):1204-7 [9120902.001]
  • [Cites] Drugs Aging. 1997 Jan;10(1):50-8 [9111707.001]
  • [Cites] J Med Chem. 1998 Mar 12;41(6):902-12 [9526564.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13317-23 [9582378.001]
  • [Cites] Curr Pharm Des. 1999 Mar;5(3):163-80 [10066888.001]
  • [Cites] Cancer Lett. 1999 Jun 1;140(1-2):27-35 [10403538.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):884s-8s [15701882.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2972-84 [15828836.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5380-9 [15958587.001]
  • [Cites] Curr Med Chem. 2005;12(14):1623-9 [16022662.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1241-6 [16287438.001]
  • [Cites] Minerva Endocrinol. 2006 Mar;31(1):1-12 [16498360.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] Pharmacol Ther. 2006 Jul;111(1):27-52 [16426683.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5033-41 [17510436.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):301-6 [17387321.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2348-57 [18723482.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1416-28 [19190349.001]
  • [Cites] Br J Cancer. 2010 Sep 28;103(7):1001-7 [20842117.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6630-40 [11118046.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2095-101 [11596025.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):41-7 [11850206.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2131-9 [12090977.001]
  • [Cites] Arch Pharm (Weinheim). 2002 Apr;335(4):119-28 [12112031.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2378-88 [12114443.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4921-31 [12118371.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1864-8 [12404279.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 15;95(2):142-53 [12529347.001]
  • [Cites] Mol Endocrinol. 2003 Mar;17(3):309-17 [12554774.001]
  • [Cites] Urol Oncol. 2003 Jul-Aug;21(4):245-54 [12954493.001]
  • [Cites] N Engl J Med. 2003 Nov 6;349(19):1793-802 [14551341.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1081-92 [15014181.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):456-65 [15026471.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2317-25 [15150570.001]
  • [Cites] J Clin Endocrinol Metab. 1973 Feb;36(2):207-14 [4688315.001]
  • [Cites] Endocrinology. 1973 Mar;92(3):866-80 [4267111.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Mar;38(3):476-9 [4815174.001]
  • [Cites] Endocrinology. 1977 Jun;100(6):1684-95 [404132.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Jan;46(1):146-52 [752017.001]
  • [Cites] Cancer Res. 1982 Aug;42(8 Suppl):3365s-3368s [7083201.001]
  • [Cites] Cancer Res. 1982 Aug;42(8 Suppl):3369s-3372s [7083202.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Apr;18(4):333-7 [6889509.001]
  • [Cites] Prostate. 1982;3(5):433-8 [6183651.001]
  • [Cites] J Urol. 1984 Jul;132(1):61-3 [6328052.001]
  • [Cites] J Urol. 1984 Oct;132(4):693-6 [6471215.001]
  • [Cites] Lancet. 1984 Dec 1;2(8414):1237-9 [6150277.001]
  • [Cites] Br J Urol. 1986 Feb;58(1):45-51 [3947856.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4823-6 [2942241.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):779-82 [3802035.001]
  • [Cites] Prostate. 1987;11(4):313-26 [2446299.001]
  • [Cites] Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):741-3 [3126957.001]
  • [Cites] Steroids. 1987 Jul-Sep;50(1-3):269-79 [3509763.001]
  • (PMID = 19111799.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA027440; United States / NCI NIH HHS / CA / R01 CA062483-28W1; United States / NCI NIH HHS / CA / R01 CA027440-23; United States / NCI NIH HHS / CA / CA-62483; United States / NCI NIH HHS / CA / CA062483-28W1; United States / NCI NIH HHS / CA / CA027440-23; United States / NCI NIH HHS / CA / R01 CA062483
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Aromatase Inhibitors; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Steroids; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; EC 1.14.14.1 / Aromatase; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Number-of-references] 80
  • [Other-IDs] NLM/ NIHMS88209; NLM/ PMC3090255
  •  go-up   go-down


77. Czecior E, Namysłowski G, Misiołek M, Scierski W, Polok A, Lisowska G, Mrówka-Kata K, Orecka B, Pawlas P: [Strategy of the sinonasal tumors treatment]. Otolaryngol Pol; 2007;61(4):559-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They state about 1% of all tumors (kidney, testum, breast, pulmonary).
  • RESULTS: In the histological examination in 4 patients the benign neoplasm and in 22 patients malignant tumors were diagnosed.
  • On the basis of the CT and MRI examination as well as the description of the surgical procedure we stated that in 13 cases the primary localization of neoplasm was the maxillary sinus, in 5 cases ethmoidal cells, in 3 nasal cavity.
  • In one patient the estimation of primary tumor localization was not possible, because of the very large extension of the neoplasm.
  • The choice of the surgical procedure was depend on the tumor extension and localization.
  • [MeSH-major] Nose Neoplasms / diagnosis. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260251.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


78. Makkat S, Luypaert R, Sourbron S, Stadnik T, De Mey J: Assessment of tumor blood flow in breast tumors with T1-dynamic contrast-enhanced MR imaging: impact of dose reduction and the use of a prebolus technique on diagnostic efficacy. J Magn Reson Imaging; 2010 Mar;31(3):556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of tumor blood flow in breast tumors with T1-dynamic contrast-enhanced MR imaging: impact of dose reduction and the use of a prebolus technique on diagnostic efficacy.
  • PURPOSE: To prospectively evaluate whether dose reduction and the application of a prebolus technique can effectively alleviate signal saturation effects in T1 dynamic contrast enhanced (T1-DCE) magnetic resonance imaging (MRI) data in breast tumors and lead to increased diagnostic efficacy of the regional tumor blood flow (TBF) values obtained with deconvolution of T1-DCE MRI data.
  • MATERIALS AND METHODS: After obtaining informed consent, 23 women (32-80 years) with histologically proven breast tumors underwent MR mammography that included a whole-breast T1 DCE sequence.
  • In the slice where the tumor enhanced maximally, a prebolus protocol was applied.
  • The relative enhancement time course from the tumor region of interest was deconvolved with the reconstructed AIF to generate the impulse response function, the maximum of which yielded the TBF.
  • RESULTS: Reducing the contrast dose by a factor of 2 led to an increase in diagnostic contrast for the TBF values of malignant and benign tumors by a factor of slightly more than 2.
  • CONCLUSION: Using a prebolus approach provides an estimate of the unsaturated AIF, while reduction of the high-dose bolus minimizes possible saturation effects in the tumor time course.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / physiopathology. Magnetic Resonance Imaging / methods. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Flow Velocity. Humans. Male. Middle Aged. Radiation Dosage. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187197.001).
  • [ISSN] 1522-2586
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Gratz S, Kempke B, Kaiser W, Behr TM, Pfestroff A, Höffken H: Unexpected 99mTc-tetrofosmin findings during myocardial perfusion scintigraphy: intraindividual comparison with PET/computed tomography. Nucl Med Commun; 2008 Nov;29(11):963-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report six patients found with unexpected mediastinal and thoracic tumor uptake during Tc-tetrofosmin myocardial perfusion scintigraphy (MPS).
  • Subsequently, the patients underwent resection of a thymoma (n=2), nonsmall cell lung cancer (n=1) and breast cancer (n=3).
  • In the patients with breast cancer one was a male patient with ductal, invasive breast cancer.
  • Benign thymomas showed high 99mTc-tetrofosmin ROI >4.0 and low F-FDG SUVmax <2.0, whereas low 99mTc-tetrofosmin ROI <2.0 were found in nonsmall cell lung cancer and breast cancer and high F-FDG SUVmax >2.5 in these malignant tumors.
  • [MeSH-minor] Aged. Breast Neoplasms, Male / complications. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Female. Humans. Lung Neoplasms / complications. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Male. Middle Aged. Myocardial Perfusion Imaging / methods. Positron-Emission Tomography / methods. Thymoma / complications. Thymoma / radiography. Thymoma / radionuclide imaging. Thymus Neoplasms / complications. Thymus Neoplasms / radiography. Thymus Neoplasms / radionuclide imaging. Tomography, Emission-Computed. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836374.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


80. Koh YW, Kim JW, Lee SW, Choi EC: Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions. Surg Endosc; 2009 Sep;23(9):2053-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions.
  • Recently, the authors developed a unilateral axillo-breast approach for endoscopic hemithyroidectomy to minimize the visible scar in a natural position and to overcome the limitation of instrumentation.
  • METHODS: This study enrolled 52 consecutive patients undergoing endoscopic hemithyroidectomy via a unilateral axillo-breast approach without gas insufflation.
  • A second 1.0-cm skin incision was made along the upper margin of the mammary areola on the tumor side for insertion of a 12-mm trocar.
  • RESULTS: Postoperative pathology showed 11 follicular adenomas, 1 follicular carcinoma, and 40 benign thyroid lesions.
  • CONCLUSION: Although the aspect of invasiveness could be improved, endoscopic hemithyroidectomy via a unilateral axillo-breast approach without gas insufflation is safe and effective and appears to provide better cosmetic results and a shorter operation time than other endoscopic methods for managing selective unilateral benign thyroid lesions.
  • [MeSH-minor] Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Axilla. Breast. Drainage. Feasibility Studies. Female. Hematoma / etiology. Humans. Length of Stay. Male. Middle Aged. Postoperative Complications / etiology. Seroma / etiology. Vocal Cord Paralysis / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Jan;22(1):154-7 [17440778.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2006 Aug;16(4):226-31 [16921301.001]
  • [Cites] Surg Endosc. 2007 Dec;21(12):2166-71 [17479328.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12 ):1741-5 [12140635.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):286-9 [11943128.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):82-5 [11044518.001]
  • [Cites] Surgery. 1997 Nov;122(5):893-901 [9369889.001]
  • [Cites] Anesth Analg. 1997 May;84(5):1154-6 [9141952.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] World J Surg. 2007 Mar;31(3):601-6 [17308853.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Jun;13(3):196-201 [12819505.001]
  • [Cites] Surg Endosc. 1997 Aug;11(8):877 [9266657.001]
  • [Cites] Arch Surg. 2002 Mar;137(3):301-4; discussion 305 [11888453.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2007 Feb;17(1):21-5 [17362173.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):20-5 [12598753.001]
  • [Cites] J Surg Oncol. 1994 Dec;57(4):235-8 [7990478.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2302-6; discussion 2307-8 [17566819.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Aug;11(4):268-72 [11525373.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):697-703 [10359365.001]
  • (PMID = 18528625.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer; 2009;9:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of PADI4 was investigated in various tumors and non-tumor tissues (n = 1673) as well as in A549, SKOV3 and U937 tumor cell lines by immunohistochemistry, real-time PCR, and western blot.
  • RESULTS: Immunohistochemistry detected significant PADI4 expression in various malignancies including breast carcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cancer cells, colorectal adenocarcinomas, renal cancer cells, ovarian adenocarcinomas, endometrial carcinomas, uterine adenocarcinomas, bladder carcinomas, chondromas, as well as other metastatic carcinomas.
  • However, PADI4 expression was not observed in benign leiomyomas of stomach, uterine myomas, endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias, hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and cavernous hemangiomas of the liver.
  • Additionally, PADI4 expression was not detected in non-tumor tissues including cholecystitis, cervicitis and synovitis of osteoarthritis, except in certain acutely inflamed tissues such as in gastritis and appendicitis.
  • Quantitative PCR and western blot analysis showed higher PADI4 expression in gastric adenocarcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cell cancers and breast cancers (n = 5 for each disease) than in the surrounding healthy tissues.
  • Furthermore, western blot analysis detected PADI4 expression in cultured tumor cell lines.
  • ELISA detected increased PADI4 and cAT levels in the blood of patients with various malignant tumors compared to those in patients with chronic inflammation and benign tumors.
  • Additionally, PADI4 and cAT levels were significantly associated with higher levels of known tumor markers.
  • [MeSH-major] Hydrolases / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Antithrombins / metabolism. Blotting, Western. Cell Line, Tumor. Citrulline / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Male. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 1998 May-Jun;84(3):364-7 [9678618.001]
  • [Cites] Pathologe. 1996 Nov;17(6):425-32 [9082363.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):498-508 [15601578.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):235-40 [15704650.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):293-8 [15561738.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):309-18 [15907383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80 [17826626.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1682-9 [18350599.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):475-83 [18509000.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4745-58 [18505818.001]
  • [Cites] Adv Exp Med Biol. 2008;630:112-32 [18637488.001]
  • [Cites] Histopathology. 2001 Jan;38(1):62-7 [11135048.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):486-92 [11973607.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):173-7 [12023846.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):201-7 [12023851.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):385-405 [15212335.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):579-82 [2114816.001]
  • [Cites] APMIS. 1991 Nov;99(11):981-8 [1720319.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(3):209-15 [1384221.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):793-806 [7686887.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • (PMID = 19183436.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Neoplasm Proteins; 29VT07BGDA / Citrulline; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2637889
  •  go-up   go-down


82. Zhang J, Park SI, Artime MC, Summy JM, Shah AN, Bomser JA, Dorfleutner A, Flynn DC, Gallick GE: AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest; 2007 Oct;117(10):2962-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using immunohistochemistry of human tissue arrays, we found that AFAP-110 was absent or expressed at very low levels in normal prostatic epithelium and benign prostatic hyperplasia but significantly increased in prostate carcinomas.
  • [MeSH-minor] Animals. Cell Adhesion / genetics. Cell Line, Tumor. Cell Movement / genetics. Cell Proliferation. Down-Regulation. Extracellular Matrix / pathology. Humans. Integrins / metabolism. Male. Mice. Mice, Nude. Mutation. Protein-Tyrosine Kinases / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2000 Feb 25;255(1):102-13 [10666339.001]
  • [Cites] Clin Exp Metastasis. 1999;17(8):713-21 [10919716.001]
  • [Cites] Lab Invest. 2000 Aug;80(8):1243-50 [10950115.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3177-82 [10955801.001]
  • [Cites] EMBO J. 2000 Oct 16;19(20):5406-17 [11032808.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 23:4139-40 [11069756.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2723-41 [11387207.001]
  • [Cites] Oncogene. 2001 Oct 1;20(44):6435-47 [11607843.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6607-16 [11641786.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):257-65 [11839777.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):48-53 [12552080.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1529-37 [12707036.001]
  • [Cites] Breast Cancer Res Treat. 2003 Apr;78(3):323-35 [12755491.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2990-6 [12782608.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):337-58 [12884910.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5161-70 [14613995.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):321-6 [14719062.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):602-20 [14755689.001]
  • [Cites] Trends Cell Biol. 2004 May;14(5):241-9 [15130580.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7578-97 [15314167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(9):3328-32 [2110361.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5192-6 [1594631.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(11):637-44 [7688749.001]
  • [Cites] Mol Cell Biol. 1993 Dec;13(12):7892-900 [8247004.001]
  • [Cites] Mol Cell Biochem. 1997 Oct;175(1-2):243-52 [9350057.001]
  • [Cites] Oncol Rep. 1998 Mar-Apr;5(2):305-9 [9468546.001]
  • [Cites] Microsc Res Tech. 1999 Oct 1;47(1):67-78 [10506763.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2568-73 [15735692.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3273-80 [15833860.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3110-20 [15735682.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):726-32 [15897236.001]
  • [Cites] Pancreas. 2005 Oct;31(3):263-74 [16163059.001]
  • [Cites] Cancer Metastasis Rev. 2005 Sep;24(3):403-11 [16258728.001]
  • [Cites] Cancer Metastasis Rev. 2005 Sep;24(3):425-39 [16258730.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1219-23 [16287434.001]
  • [Cites] Clin Exp Metastasis. 2005;22(7):565-73 [16475027.001]
  • [Cites] J Nutr Biochem. 2006 Mar;17(3):204-10 [16198100.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):962-72 [16507911.001]
  • [Cites] Exp Cell Res. 2006 May 15;312(9):1658-70 [16527272.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1213-8 [16632344.001]
  • [Cites] Angiogenesis. 2006;9(2):101-10 [16871430.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):745-56 [16862179.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):740-9 [17520695.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1904-14 [12060635.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2311-22 [12134071.001]
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):90-3 [12546661.001]
  • (PMID = 17885682.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFAP 110; 0 / Integrins; 0 / Microfilament Proteins; 0 / Phosphoproteins; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC1978423
  •  go-up   go-down


83. Dragoumis D, Atmatzidis S, Chatzimavroudis G, Lakis S, Panagiotopoulou K, Atmatzidis K: Benign spindle cell tumor not otherwise specified (NOS) in a male breast. Int J Surg Pathol; 2010 Dec;18(6):575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign spindle cell tumor not otherwise specified (NOS) in a male breast.
  • Breast spindle cell tumors (BSCTs), although uncommon, constitute a heterogeneous group of benign and malignant lesions, often necessitating different therapeutic approaches.
  • This study describes the case of a 62-year-old man who displayed a gradually growing retroareolar tumor of the left breast.
  • Diverse histological results and immunohistochemical features established the diagnosis of benign BSCT, not otherwise specified.
  • This case report adds to the spectrum of the benign BSCTs and delineates the nature of different types of these lesions, in order to carefully select optimal therapeutic regimes.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064588.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


84. Beatty JS, Williams HT, Aldridge BA, Hughes MP, Vasudeva VS, Gucwa AL, David GS, Lind DS, Kruse EJ, McLoughlin JM: Incidental PET/CT findings in the cancer patient: how should they be managed? Surgery; 2009 Aug;146(2):274-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 133 patients evaluated further, clinicians identified a second primary malignancy in 41 patients (31%), benign disease in 62 patients (47%), and metastatic disease from their known malignancy in 30 patients (23%).
  • The most common sites for a proven second primary malignancy were: lung (N = 10), breast (N = 7), and colon (N = 5).
  • In our data, approximately half of these findings were benign, a third were consistent with a second primary malignancy or a metastatic focus, and the remainder were never evaluated due to physician and patient decision.
  • Advanced primary tumors are unlikely to be impacted by a second primary tumor suggesting that this subset of patients will not benefit from further investigation.
  • The timing and route of investigation should be dictated by clinical judgment and the status of the primary tumor.
  • [MeSH-major] Incidental Findings. Neoplasms, Second Primary / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Radiopharmaceuticals. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628085.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


86. Khalifeh I, Taraif S, Reed JA, Lazar AF, Diwan AH, Prieto VG: A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ. Am J Surg Pathol; 2007 Jul;31(7):1130-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanocytic lesions in certain locations (eg, genital, breast, acral) may have histologic and clinical features simulating melanoma.
  • One hundred fifteen melanocytic lesions from the ankle were retrieved from January 1990 to August 2006 from the files of M. D.
  • Anderson Cancer Center and were classified as benign melanocytic nevi (BN; n=17), DN (n=35), melanomas (MM; n=52), and melanocytic nevi of the ankle with atypical features (MNAAF; ie, cases that did not readily fit in any of the previous categories, n=11).
  • All MNAAF showed moderate-severe architectural disorder whereas 78% showed only mild-moderate cytologic atypia.
  • After complete excision, follow-up data indicate an apparently benign outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ankle. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male. Melanins / metabolism. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592281.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Melanins
  •  go-up   go-down


87. Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A: Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol; 2007 Jan;35(1):6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens evaluated included four pleural (3 benign, 1 breast adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions.
  • [MeSH-major] Artifacts. Ascitic Fluid / pathology. Cytodiagnosis / methods. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Specimen Handling / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Time Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173298.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


88. Abdul M, Hoosein N: N-methyl-D-aspartate receptor in human prostate cancer. J Membr Biol; 2005 Jun;205(3):125-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 18 benign prostatic hyperplasia (BPH) specimens, none had stromal NMDAr staining, but 2 had low and 1 had high epithelial NMDAr immunoreactivity.
  • We have also examined the effects of the NMDAr antagonist memantine on the growth of ten human cancer cell lines: four prostate, two breast and four colon.
  • [MeSH-minor] Breast / metabolism. Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Colonic Neoplasms. Cysteine / analogs & derivatives. Cysteine / pharmacology. Dizocilpine Maleate / pharmacology. Humans. Immunohistochemistry. Male. Memantine / pharmacology. Prostate / physiology. Prostatic Hyperplasia / physiopathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. MEMANTINE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2004 Jan 21;291(3):317-24 [14734594.001]
  • [Cites] Mol Chem Neuropathol. 1997 Jan-Feb;30(1-2):77-94 [9138430.001]
  • [Cites] Neuropharmacology. 1999 Jun;38(6):735-67 [10465680.001]
  • [Cites] Cancer Lett. 2002 Dec 1;186(1):99-105 [12183081.001]
  • [Cites] J Neurosci Res. 1996 Oct 15;46(2):164-78 [8915893.001]
  • [Cites] J Androl. 2000 Jul-Aug;21(4):566-78 [10901443.001]
  • [Cites] Trends Pharmacol Sci. 2001 Apr;22(4):174-81 [11282417.001]
  • [Cites] J Nutr. 2000 Apr;130(4S Suppl):1007S-15S [10736372.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 15;64(8):1195-200 [12234599.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7 [11331750.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • (PMID = 16362500.001).
  • [ISSN] 0022-2631
  • [Journal-full-title] The Journal of membrane biology
  • [ISO-abbreviation] J. Membr. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, N-Methyl-D-Aspartate; 2381-08-0 / cysteine sulfinic acid; 6LR8C1B66Q / Dizocilpine Maleate; K848JZ4886 / Cysteine; W8O17SJF3T / Memantine
  •  go-up   go-down


89. Li JS, Sun GW, Wei XY, Tang WH: Expression of periostin and its clinicopathological relevance in gastric cancer. World J Gastroenterol; 2007 Oct 21;13(39):5261-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry was performed to localize and quantify the expression of periostin in benign gastric diseases and gastric cancer, and immunostaining results were correlated with gastric cancer pathological stages.
  • Immunohistochemical staining revealed that periostin was overexpressed in primary gastric cancer, as well as in metastatic lymph nodes, but only faint staining was found in benign gastric ulcers.
  • By quantitative analysis of the immunostaining results, periostin expression was increased 2.5-4-fold in gastric cancer, compared to that in benign gastric disease, and there was a trend toward increasing periostin expression with tumor stage.
  • [MeSH-minor] Aged. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Stomach / metabolism. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876898.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC4171309
  •  go-up   go-down


90. Böttger T, Terzic A, Müller M: [Laparoscopic pancreatic resection]. Zentralbl Chir; 2006 Aug;131(4):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In all four cases laparoscopic distal pancreatic resection was performed for tumor.
  • Histologic examination showed a neuroendocrine carcinoma, a serous-microcystic adenoma, a low differentiated ductal adenocarcinoma and an intraductal papillary-mucinous tumor of borderline type.
  • CONCLUSION: Laparoscopic resection of distal pancreas shows the common benefit of minimal invasive surgery for the early postoperative period and is an attractive alternative for treatment of benign and semimalign pancreatic tumors.
  • [MeSH-major] Adenoma / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Neuroendocrine / surgery. Cystadenoma, Mucinous / surgery. Laparoscopy. Pancreas / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Fundoplication. Gastroesophageal Reflux / surgery. Humans. Length of Stay. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Middle Aged. Minimally Invasive Surgical Procedures. Positron-Emission Tomography. Radiography, Abdominal. Spleen / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004190.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J: Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol; 2007 Nov;38(11):1628-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.
  • The purpose of this study was to understand the characteristics of prostate-derived Ets factor (PDEF) protein expression in breast and prostate cancer progression.
  • A polyclonal antibody specific to PDEF was raised and reacted with tissue microarrays consisting of benign breast, in situ ductal, invasive ductal, and invasive lobular breast carcinomas.
  • The antibody was also reacted with tissue microarrays, including benign prostate, prostate intraepithelial neoplasias (PINs), and prostate carcinomas.
  • Increased expression of PDEF was identified in 18%, 50%, 46%, and 51% of benign breast tissues, intraductal, invasive ductal, and invasive lobular carcinomas, respectively.
  • Importantly, in matched samples of benign breast vs tumor, 90% showed higher expression of PDEF in the tumor tissue.
  • Moreover, in invasive breast carcinomas, increased PDEF expression tended to correlate with Her2/neu overexpression.
  • Increased expression of PDEF was also found in 27%, 33%, and 40% of benign prostate tissues, PIN samples, and prostate adenocarcinomas, respectively.
  • Again, in matching samples of cancer vs benign and cancer vs PIN, 68% and 70%, respectively, showed increased expression in the malignant tissue.
  • In addition, R1881 treatment induced PDEF expression in the LNCaP prostate tumor cell line, suggesting regulation of PDEF by androgens in vivo.
  • Together, these results for the first time show frequent increased expression of PDEF protein in breast and prostate tumors and support a role for PDEF in breast and prostate cancer progression.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Steroids. 2007 Jan;72(1):7-25 [17169390.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):176-84 [16858179.001]
  • [Cites] Cancer Biol Ther. 2007 Jan;6(1):76-82 [17172821.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):19-30 [16897429.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1216-25 [10625666.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1348-52 [10728697.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Crit Rev Oncog. 2000;11(3-4):227-53 [11358268.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2731-8 [11555586.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37 [11715049.001]
  • [Cites] Bioessays. 2002 Apr;24(4):362-70 [11948622.001]
  • [Cites] Climacteric. 2002 Mar;5(1):15-25 [11974555.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Apr;17(2):137-49 [12030108.001]
  • [Cites] Curr Cancer Drug Targets. 2001 May;1(1):49-57 [12188891.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4626-31 [12907642.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11281-92 [14662758.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):459-76 [15369448.001]
  • [Cites] BMJ. 1997 Jun 28;314(7098):1843-4 [9224112.001]
  • [Cites] Breast Cancer Res. 2004;6(6):229-39 [15535852.001]
  • [Cites] Annu Rev Med. 2005;56:117-37 [15660505.001]
  • [Cites] Curr Opin Urol. 2005 May;15(3):181-6 [15815195.001]
  • [Cites] Curr Opin Urol. 2005 May;15(3):187-95 [15815196.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):257-60 [15818171.001]
  • [Cites] J Endocrinol Invest. 2005;28(3 Suppl):8-13 [16044581.001]
  • [Cites] Curr Pharm Des. 2005;11(22):2873-87 [16101443.001]
  • [Cites] Am J Pharmacogenomics. 2005;5(5):327-38 [16196502.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11572-80 [16357167.001]
  • [Cites] Curr Gene Ther. 2006 Feb;6(1):17-33 [16475943.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):1-7 [16790693.001]
  • (PMID = 17521701.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA 86164; United States / NCI NIH HHS / CA / CA086164-03; United States / NCI NIH HHS / CA / R41 CA086164-03; United States / NCI NIH HHS / CA / P30 CA 16056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-ets; 0 / SPDEF protein, human; 2C323EGI97 / Metribolone
  • [Other-IDs] NLM/ NIHMS33974; NLM/ PMC2121591
  •  go-up   go-down


92. Ferbeyre-Binelfa L, Ramírez-Bollas J, Bautista-Piña V, Espejo-Fonseca R, Ruvalcaba-Limón E, Serratos-Garduño E: [Fibromatosis of the breast. Report of two cases and review of the literature]. Cir Cir; 2009 Jul-Aug;77(4):313-8; 291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibromatosis of the breast. Report of two cases and review of the literature].
  • BACKGROUND: Fibromatosis is a term used to describe a group of lesions characterized by well-differentiated fibroblast proliferation with an usually benign biological behavior but with an infiltrative pattern of growth, frequently recurrent and locally invasive.
  • The presence of this entity in breast tissue is an uncommon clinical situation, comprising approximately 0.2% of breast tumors and very often misdiagnosed as malignant disease or phyllodes tumor.
  • In this rare condition, immunohistochemistry is an important diagnostic tool in anatomopathological differential diagnosis with other spindle cell tumors of the breast.
  • CLINICAL CASES: We present two cases of breast fibromatosis confirmed immunohistochemically and also by biopsy.
  • One case had the clinical and imaging appearance of breast carcinoma with the classic irregular mass presentation and the other case was misdiagnosed as phyllodes tumor because of the size and density of the tumor and the cytology.
  • CONCLUSIONS: Approximately 83 cases of breast fibromatosis have been reported during the last 30 years, including one male patient.
  • We reviewed clinicopathological features of two cases of fibromatosis of the breast treated at our institute.
  • [MeSH-major] Breast Neoplasms / diagnosis. Fibroma / diagnosis

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919794.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 44
  •  go-up   go-down


93. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF, Gardiner RA: Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer; 2008 Aug 5;99(3):491-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Claudin-4, coding for an integral membrane cell-junction protein, was the most significantly (P<0.00001) upregulated marker in both primary and metastatic tumour specimens compared with benign prostatic hyperplasia at both RNA and protein levels.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Membrane Proteins / metabolism. Prostatic Neoplasms / pathology. Prostatic Neoplasms / secondary
  • [MeSH-minor] Base Sequence. Blotting, Western. Cell Line, Tumor. Claudin-4. DNA Primers. Humans. Immunohistochemistry. Male. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction